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ABSTRACT 
 
Thiazide diuretics are a recommended first-line monotherapy for hypertension 
(i.e.SBP>140 mmHg or DBP>90 mmHg). Even so, diuretics are associated with adverse 
metabolic side effects, such as hyperlipidemia, hyperglycemia and hypokalemia which 
increase the risk of developing type II diabetes. This thesis used three analytical strategies 
to identify and quantify genetic factors that contribute to the development of adverse 
metabolic effects due to thiazide diuretic treatment. I performed a genome-wide association 
study (GWAS) and meta-analysis of the change in fasting plasma glucose and triglycerides 
in response to HCTZ from two different clinical trials: the Pharmacogenomic Evaluation of 
Antihypertensive Responses (PEAR) and the Genetic Epidemiology of Responses to 
Antihypertensive (GERA) studies. Two SNPs (rs12279250 and rs4319515 (r2=0.73)), 
located at 11p15.1 in the NELL1 gene, achieved genome-wide significance for association 
with change in fasting plasma triglycerides in African Americans, whereby each variant allele 
was associated with a 28 mg/dl increase in the change in triglycerides. NELL1 encodes a 
cytoplasmic protein that contains epidermal growth factor (EGF)-like repeats and has been 
shown to represses adipogenic differentiation. No statistical significant association was 
found in the case of change in glucose or change in triglycerides in European-Americans in 
this study. 
In order to increase the sample size and signal for the change in glucose, I 
performed a GWAS of longitudinal data and meta-analysis from 14 cohorts which are part of 
the CHARGE consortium. No statistically significant association was found. The lack of 
positive results in this analysis suggested that it is unlikely that there is a single common 
SNP with a large effect on the adverse reaction to the diuretic use. Therefore, we can 
speculate about the possible interaction of multiple variants each with modest effect sizes or 
the fact that rare variants are playing a greater part in this particular phenotype. 
Finally, I performed a genome-wide association study and a Multi-Ethnic Meta-
Analysis of change in blood potassium levels 718 European- and African-American 
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hypertensive participants. SNPs rs10845697 (Bayes Factor=5.560) on chromosome 12, 
near to the HEME binding protein 1 gene, and rs11135740 (Bayes Factor= 5.258) on 
chromosome 8 near the Mitoferrin-1 gene reached GWAS significance (Bayes Factor > 5). 
These results, if replicated, suggested a novel mechanism involving effects of genes in the 
HEME pathway influencing hydrochlorothiazide-induced renal potassium loss. 
 The main goal of this research was to explore first steps in developing 
hydrochlorothiazide personalize medicine in order to provide a lasting and positive impact 
on public health.  
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CHAPTER 1:  BACKGROUND AND SIGNIFICANCE 
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1.1 Definition of BP and hypertension 
 
The beating heart is the most important organ in the circulatory system which is 
responsible for delivering nutrients and oxygen to all cells in the body as well as removing 
waste that the cells produce as a result of normal respiration. To accomplish this function, 
the heart needs to repeatedly contract (i.e. systole), and relax (i.e. diastole). The heart 
consists of 4 chambers, two atria in the upper part and two ventricles in the lower part. This 
pumping action generates a blood pressure (BP) within the circulatory system. Contraction 
or systole of the left ventricle opens the aortic valve and pushes oxygenated blood into the 
aorta. This phenomenon causes the artery’s wall to stretch and the pressure to rise to a 
maximum that is called the systolic blood pressure (SBP). The pressure in the aorta falls 
during relaxation or diastole of the left ventricle allowing the closing of the aortic valve. 
Before the left atrium contracts again, the pressure in the aorta reaches a minimum that is 
called the diastolic blood pressure (DBP)1.  
 
Average values of SBP and DBP at birth are approximately 70 and 50mmHg, 
respectively, but increase to 120 and 80mmHg during adulthood2. In westernized 
populations, SBP continues to rise throughout life reaching an average value of 140mmHg 
by the seventh decade3. In the case of DBP, it reaches an average value of 80mmHg by the 
fifth decade where it tends to be flat or even decline3. Isolated non-westernized populations 
do not show a significant age-related increase in BP in adulthood after reaching the “normal 
BP values” from normal growth4. Interestingly, this pattern changes when individuals from 
these isolated population migrate to western cultures5.  
 
Prominent factors that influence the age-related increase in blood pressure are gender, 
ethnicity, earlier blood pressure levels, obesity and excess salt intake. When individuals 
reach adolescence, BP levels in men are on average higher than in women. This difference 
disappears in later stages of life and in fact is reversed at older ages, perhaps due to higher 
mortality in hypertensive men3. Considering ethnicity, Hispanics have lower BP levels than 
Caucasians and Asians6. The BP of African-Americans increases more sharply during their 
second decade than Whites6. In the case of previous BP levels, it is well known that BP 
values in a population are distributed as a near Gaussian distribution4 and that members of 
the population tend to remain in the same relative position of the BP distribution later in life7, 
8. This phenomenon is known as “tracking”. The US Health and Nutrition Education Survey 
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shows the tendency that individuals in the upper percentiles of the BP distribution have a 
greater age-related increase in BP than the rest of the population9. In reference to obesity, 
the Framingham study reported a clear relationship between the excess adipose cells, 
which is a main characteristic of obese individuals, and an increase of SBP10. The trend was 
4.5mmHg average increase of SBP for every 4.5 kg of weight gain. Finally in the case of salt 
intake, an early experiment was conducted in 500 newborn infants for 6 month, in which the 
sodium intake was reduced by half in 250 newborn11. This study showed that by reducing 
the sodium intake, SBP was reduced by 2.1mmHg in comparison a newborn with normal 
sodium intake. Later on, two studies showed that patients (with or without hypertension) who 
restrict their sodium intake for 36 month12 to 5 years13 had reduced BP levels and decrease 
incidence of hypertension compared to patients without a reduction in sodium intake.  
 
Inter-individual differences in BP values may be influenced by genetic differences among 
individuals, shared environmental factors such as a household or school effects, and factors 
that are unique to an individual, including measurement error. All of these factors that 
influence inter-individual BP variability can be investigated in family studies where familial 
aggregation of BP values occur4. The Montreal Adoption14, 15study showed strong correlation 
coefficients for SBP and DBP between related individuals that share genetic factors as well 
as environmental factors16. On the other hand, the correlation coefficients for SBP and DBP 
in unrelated individuals who only share environmental factors are lower (Table 1.). Taken 
together, I conclude that there are clear genetic and environmental factors that influence 
interindividual BP variability. 
 
In December 2003, the Joint National Committee on the Prevention, Detection, 
Evaluation and Treatment of High Blood Pressure (JNC) VII report was published2 and four 
classifications for blood pressure were introduced (Table 1.). According to this report, 
hypertension is defined as high SBP and DBP values (more than 140mmHg or 90mmHg 
respectively). When the causes of elevated SBP and/or DBP are unknown, the term 
“essential hypertension” is used. On the other hand, the term “secondary hypertension” is 
given to cases in which the reasons for hypertension are well known such as renal artery 
stenosis, bilateral renal parenchymal disease, primary aldosteronism, pheochromocytoma, 
Cushing’s syndrome and oral contraceptive agents. Over 95% of adult hypertension is 
essential hypertension17. 
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*total pairs of relative compared; +p=0.001; &p=0.01 
Relationship N* SBP DBP 
Spouses 521 0.146+ 0.175+ 
Father-Natural Child 198 0.237+ 0.205& 
Mother-Natural Child 198 0.271+ 0.260+ 
Natural Siblings 94 0.382+ 0.525+ 
Father-Adopted Child 442 0.089 0.134& 
Mother- Adopted Child 442 0.078 0.099 
Adopted Siblings 154 0.164 0.285+ 
Natural child- Adopted 
child 
119 0.186 0.269+ 
Table 1.1: Estimated SBP and DBP correlation between household members14, 15 
 
 
 
*based on blood pressure values alone 
 
Blood Pressure 
Classification 
 
 
SBP 
mmHg 
 
 
DBP 
mmHg 
 
Lifestyle 
Modification 
Drug 
Therapy* 
Normal <120 and <80 No No 
Prehypertension 120–139 or 80–89 Encourage No 
Hypertension 
Stage 1 
140–159 or 90–99 Yes Yes 
Hypertension 
Stage 2 
>160 or >100 Yes Yes 
Table 1.2 Classification of blood pressure for adults 
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1.2 Hypertension as Cardiovascular Risk Factor 
 
Multiple studies have showed a consistent and continuous relationship between 
hypertension and risk of cardiovascular disease (CVD) events (atherosclerosis18, 
hypertension retinopathy19, coronary artery disease, stroke, myocardial infarction and kidney 
disease2, 20, 21). Lewington et al22 performed meta-analysis of 61 prospective studies that 
included 1 million individuals; this analysis indicated that stroke and ischemic heart disease 
(IHD) increase linearly with BP levels. The Framingham Heart Study23 reported that 
individuals, with BP classified as prehypertensive or stage 1 hypertension, have a two-fold 
increased risk to develop CVD compared to individuals with normal BP. The National High 
Blood Pressure Education Program and other public health programs aim to increase the 
control of hypertension and its treatment to reduce morbidity and mortality in the American 
population2, 24. However, the prevalence of hypertension between 1999 and 2006 did not 
show a significant decline (28% to 30% respectively). In addition, among those with 
hypertension, only 78% are aware of their condition, and of them, only 68% are using 
antihypertensive medication, and of them, only 64% are able to control their BP below the 
recommended levels (BP less than 140/90mmHg)25. In general, hypertension affects 28% of 
the adult population in America; and continues to be a significant contributor to morbidity 
and mortality in the United States. 
1.3 Treatment of Hypertension 
 
The primary guidelines for the prevention and treatment of hypertension in the United 
State are published by the U. S. Department of Health and Human Services, and its most 
recent guidelines are given in “The Seventh Report of the Joint National Committee on 
Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report” 
(JNC VII)2.  According to JNC VII, the main objective of antihypertensive therapy is to 
reduce SBP levels below 140mmHg; and DBP rates to 90mmHg in order to decrease CVD 
complications26. However, in patients with diabetes or renal disease the goals are below 
130mmHg for SBP and below 80mmHg for DBP27. 
 
To reach these goals, lifestyle modification 28,29,30,31, 32 and pharmacological treatment 
are needed. With respect to pharmacologic treatment, there are diverse drug classes that 
can be used to control hypertension such as: thiazide diuretics (TZDs), beta blockers (BBs), 
angiotensin II antagonist, aldosterone receptors blockers (ARB), angiotensin converting 
enzyme inhibitors (ACEI), and calcium channels blockers (CCB). 
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Most hypertensive patients need a combination of drug classes to control their 
hypertension33, 34. As an example, in the ALLHAT study, 60 % of patients on a two drugs 
class treatment were able to reduce their BP to less than 140/90mmHg in comparison with 
30% that achieved the same goal with only one drug treatment35. The JNC VII report cites 
the findings from the ALLHAT study, which showed35 that the primary coronary heart 
disease(CHD) outcome and mortality among patients using chlorthalidone (thiazide diuretic-
like), or  lisinopril (ACEI) or amlodipine (CCB) were not different, suggesting the use of  
thiazide diuretics, due to their cheaper price, as the main drug (either alone or in 
combination with other drugs) to control hypertension. 
 
Thiazide diuretics act mainly in the cortical portion of the ascending loop of Henlé (ALH) 
and the distant convoluted tubule (DCT) after being excreted into the lumen by OCT1, 
coded for by the SLC22A6 gene, and OCT3 coded for by the SLC22A8 gene36. The main 
target of thiazide diuretics is the electro-neutral Na+-Cl- symporter (NCC).  The NCC 
reabsorbs Na+ and Cl- from the lumen of the tubule into the tubular cells due to the higher 
concentration of sodium in the ALH and DCT. This sodium gradient is produced by the 
depletion of sodium and gain of potassium from the tubular cell due to the Na+-K+-ATPase 
antiport. This antiport is located in the basolateral membrane in the tubular cells. The NCC 
binds sodium first which then increases the affinity for chloride at its binding site on the 
symporter. When both ions are bound, the symporter transfers both Na+ and Cl- into the 
tubular cells. TZDs inhibit the reabsorption of sodium and chloride by the symporter, but the 
detailed way that the inhibition occurs is still unknown. It has been speculated that TZDs 
compete with chloride for the chloride binding site37. TZDs also increase the excretion of 
potassium and hydrogen ion for sodium at the DCT. It is not surprising then, that some 
mutations in the NCC lead to the inherited hypokalemic alkalosis called Gitelman 
syndrome38-40 
 
The Veterans Administration Cooperative Study on Antihypertensive Agents41, trial 
showed the importance of TZDs not only as antihypertensive drug therapy, but also as a 
way to reduce CVD events (such Strokes, CHD and heart failure (HF)). Antihypertensive 
drugs like aldosterone receptors blockers, angiotensin converting enzyme inhibitors, beta 
blockers and calcium channel blockers have been used over the years in multiple clinical 
trials33, 34, 42-46 with similar as in the case of TZDs. However, the ALLHAT clinical trial with 
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more than 40000 hypertensive individuals, showed that the incidence of HF was greater in 
those randomized to the CCB arm compared to those to the TZDs.   
1.4 Hydrochlorothiazide Treatment and its adverse effects  
 
Hydrochlorothiazide (HCTZ), amongthethiazide diuretics, is one of the most common 
prescribed drugs for BP control2, but some adverse effects have been reported. These 
adverse effects can be classified into three main groups: physiological problems47, 48, 
electrolyte defects (hyperuricemia, hyponatremia, and hypokalemia), and metabolic 
abnormalities (hyperlipidemia and hyperglycemia)49. In the paragraphs below, I review each 
of these adverse effects individually. 
Hyperuricemia is defined as a serum uric acid concentration greater than 0.42mmol/L50. 
It has been observed that patients treated with HCZT showed average levels of serum uric 
acid of 0.54mmol/L51. When HCZT is taken, it competes with the uric acid for transport into 
the cell52. This process results in hyperuricemia in HCZT-treated hypertensive patients. 
Hyponatremia is defined as serum sodium level less than 134mmol/L and approximately 
11% of geriatric patients treated with HCZT to control their blood pressure develop 
hyponatremia53. Due to the activity of HCZT in the distal tubule, the activity of the antidiuretic 
hormone (ADH) is enhanced so that water re-absorption occurs. As a result, the 
concentration of Na in urine is higher than the concentration in plasma54, 55. 
Hypokalemia is defined as serum K+ concentration less than 3.5mmol/L. Approximately 
50% of patients treated with HCZT to control their blood pressure develop hypokalemia56. 
The physiological mechanism responsible for the increase of K+ excretion in the urine is 
thought to be inhibition of the renal sodium chloride co-transporter (symport) by HCZT57. 
This inhibition increases the amount of sodium and water in the distal convolute tubule and 
consequently the flow rate of urine. The increase in the flow rate stimulates distal potassium 
secretion due to the wash-out of K from the lumen58.  
Dyslipidemia is defined as the alteration of the amount of lipids in the blood. It has been 
shown that patients using HZCT treatment for a short-term have modest increases in the 
amount of LDL-cholesterol and triglycerides levels but HDL-cholesterol level does not show 
any significant change49, 59, 60. As in the case of hyperglycemia, there is no agreed-upon 
mechanism for how HZCT influences lipid concentration in the blood. The main hypothesis 
involves increased insulin sensitivity in  patients as well as increased activity in the RAA 
system49.      
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Hyperglycemia is defined as high blood sugar. Two different epidemiologic studies61, 62 
have reported an association between new-onset diabetes or hyperglycemia with HZCT 
treatment for hypertension. The precise mechanisms of how HZCT influences 
hyperglycemia are not well understood but there are two contemporary hypotheses. The first 
one suggests that due to the block of the renal sodium chloride channel by HZCT, the 
amount of excreted sodium increases, causing excretion of potassium in the urine63. The 
second hypothesis states that due to the blood volume depletion resulting from HZCT, the 
RAA system is activated, allowing aldosterone secretion which leads to increased potassium 
secretion63. In either scenario, the hypotheses conclude that hypokalemia induces higher 
proinsulin secretion over insulin. Proinsulin is less active than insulin. Therefore the 
concentration of glucose in the blood increases56. It is my hope that additional insight into 
the underlying mechanism of the metabolic side effects of diuretics will be obtained by 
identifying genes contributing to the glucose-related response to diuretic therapy (Chapter 2 
and 4). 
In recent years, it has been theorized that HCTZ may promote kidney damage47, 48.  
Although the main mechanisms remains unclear, animal models have shown that the use of 
thiazide chronically induces the wrinkling and thickening of the glomerular basement64 as 
well as apoptosis in distal tubule cells65, 66. 
1.5 Role of potassium 
 
On average, the total amount of potassium in the human body is 53.8mmol/kg body 
weight; 2% is found in the extracellular spaces and 98% is intracellular67, 68. The plasma 
concentration of potassium is kept between 3.5mEq/L to 5.0mEq/L. The balance of 
potassium concentration and distribution is regulated by four main mechanisms: 1) the 
gastrointestinal tract, 2) the Na+-K+-ATPase in the plasma membrane which is controlled by 
several hormones, 3) activity of the sympathetic nervous system, and 4) the kidneys. Each 
mechanism is discussed below: 
 
1) The gastrointestinal tract absorbs most of the dietary intake of potassium, which 
on average is 100mmol/day (80 to 120mmol/day)67, 69. However, 5% to 10% of 
the dietary potassium is excreted through the feces. The colon is incapable of 
increasing potassium secretion by itself, but during an episode of diarrhea68, the 
loss of potassium could reach 30% to 60%.  
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2) The Na+-K+-ATPase pump keeps the transmembrane gradients of Na+ and K+70 
in equilibrium. When sodium enters the cytosol, it produces a change in the 
membrane potential (also known as hyperpolarization) due to the unequal exit of 
potassium (three of Na+ for two of K+) to the lumen. Hyperpolarization is a 
phenomenon that occurs before muscular movement.     
 
3) Due to the interaction between the neurohumoral mediators (acetylcholine, 
substance P) and their receptors in endothelial cells, the concentration of calcium 
increases, the first step for the endothelium-derived hyperpolarizing factor or 
EDHF-mediated response. The increase of intracellular calcium activates two 
different potassium channels, known as the calcium-activated potassium 
channels of small and intermediate conductance (SKCa, and IKCa respectively)
70, 
71. These channels release potassium to the lumen of the blood vessel as well as 
to the intercellular space between endothelial and smooth muscle cells. 
Endothelial cells take advantage of the hyperpolarization of vascular smooth cells 
to regulate the diameter of blood vessels by the EDHF70, 71 in which potassium 
plays an important role. 
 
4) The last mechanism in the regulation of potassium concentration occurs in the 
kidneys, where potassium is excreted by a combination of filtration, reabsorption 
and secretion. All of these steps occur primarily in nephrons, which are formed 
by eight parts (Figure 1.5.1): 1) the glomerulus, 2) the proximal tubule, divided in 
two parts: the convoluted tubule (PCT) and the proximal straight tubule (PST), 
3)Henle’s loop which consists of thin descending limb of Henle’s loop (tDHL), thin 
ascending limb of Henle’s loop (tALH) and thick ascending limb of Henle’s loop 
(TAL), 4) the distal convoluted tubule (DCT), 5) the connecting tubule (CNT), 6) 
the initial convoluted tubule (ICT), 7) the cortical collecting tubule (CCT), and 8) 
the medullary collecting tubule (MCD) which consists of the outer medullary 
collecting duct (OMCD) and the  inner medullary collecting tubule (IMCD). 
Around ~800mmol of potassium is filtered in the glomerulus every day. Most of it, 
approximately 80%, is reabsorbed by the PCT and 10% at the loop of  
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Figure 1.5.1: Potassium handling in superficial nephrons. Schematic was taken from 
Medical Physiology by Boron and Boulpaep67. PCT(proximal convoluted tubule), 
PST(proximal straight tubule), tDHL(thin descending limb of Henle’s loop), tALH(thin 
ascending limb of Henle’s loop), TAL(thick ascending limb of Henle’s loop), DCT(distal 
convoluted tubule), CNT(connecting tubule), ICT(initial convoluted tubule), CCT(cortical 
collecting tubule), OMCD(outer medullary collecting duct), IMCD(inner medullary collecting 
tubule)  
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Henle. Only 10% of potassium reaches the DCT and finally the MCD reabsorbs 
around 20% to 40% (of the remaining 10%) the rest is excreted in the urine67, 68. Low 
dietary potassium intake stimulates its absorption which occurs in the classic distal 
tubule (DCT, CNT, and ICT) and CCT67 and decreases the activity of Big-potassium 
(BK) and renal outer medullary potassium (ROMK) channels. On the other hand, in 
high dietary potassium intake, nephrons will secrete potassium to the tubule lumen 
mainly from the distal K+ secretory system (CNT, ICT, CCT and OMCD)67. The 
secretion of potassium is mediated by aldosterone-dependent and aldosterone-
independent mechanisms72. The release of aldosterone increases ROMK and BK 
channels in CNT and CCT. 
 
Thiazide diuretics reduce blood pressure by reducing plasma volume due to diuresis. 
HCTZ diuretics block the renal sodium chloride channel which increases the amount of 
sodium, chloride and water that is excreted5. The high sodium load-in the distal tubule-
produces, an increase in the excretion of potassium due to the high activity of the Na+-K+-
ATPase pump. Furthermore, the increase in potassium in the collecting tubes facilitates the 
exchange of K+ for H+ by H+-K+-exchangers in the intercalated alpha cells producing 
alkalosis. Diuretic hypovolemia, also, activates the renin-angiotensin-aldosterone system 
(RAAS)63 producing more aldosterone which stimulates the Na+-K+-ATPase pump, resulting 
in more loss of potassium.  
1.6 Pharmacogenetics and Pharmacogenomics 
 
Response to any pharmacological treatment is remarkably variable among individuals. 
Some patients respond favorably to a drug while others may have no (or even adverse) 
response to the same drug. Reasons for this variability in drug response can be explained 
by drug interaction, patients’ age, nutritional status, liver or renal activity and the 
pathogenesis of the treated disease. Early investigators73, 74 showed evidence of variation in 
genes that code for drug receptors, in genes that code for proteins that metabolize the drugs 
and influence drug response genes that code drug transporters. As a result, 
pharmacogenetics appeared as the science that studies the relationship between drug 
response and genetic variation.  
Most previous pharmacogenetic studies have been based on a candidate gene 
approach, in which genes that influence pharmacological response (drug transport, drug 
metabolism and drug targets) are targeted to see how their variation influences drug 
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response66. In most cases, multiple genes are acting in concert to influence drug response75. 
To consider all possible genes, pharmacogenetics morphed its name to pharmacogenomics, 
where a key approach is the genome-wide association (GWA) study, in which we do not 
need to invoke a priori candidate genes but we can identify and estimate possible 
associations among all genes and drug response.     
Relevant to pharmacogenomics, there are two main problems that all clinicians face. 
First, not everybody equally metabolizes a drug76. In real life, clinicians are forced to address 
“trial and error” approach in order to administrate the right drug dose that can help every 
patient. The second problem is Adverse Drug Reactions (ADR) that result from many drugs 
treatments. These ADRs produce illness and in some cases even death. In a typical 
hospital, 3 to 11% of its ER admissions are related ADRs77, which leads to 2 million 
admissions in a year and 110,000 deaths in the same period of time due to ADRs. These 
estimates put ADRs between the 4th to 6th leading causes of death in the United States77, 
with an estimated cost of more than $4 billion78.  A goal of pharmacogenomics is to tailor 
therapy selection to improve drug treatment as well as to reduce ADRs. The warfarin drug 
case is a good example of what pharmacogenetics can accomplish. 
Warfarin is a common drug that is used as an oral anticoagulant79. It targets the vitamin 
K cycle which is important in the carboxylation of the glutamic acid residues that are found in 
clotting factors. Warfarin is metabolized by CYP2C9; there are two significant alternative 
functional versions of the enzyme that are common in populations of European ancestry, the 
CYP2C9*2 (Arg144Cys) and CYP2C9*3(Ile359Leu)79. If a patient is at risk for thrombosis 
and has the CYP2C9*3/*3 variant, normal doses of warfarin will not be effective, and a lower 
concentration of the drug will be needed.  On the other hand, if the patient has the 
CYP2C9*1/*1 variant of the enzyme, a normal dose of warfarin will be effective.  Therefore, 
knowing in advance the genotype of CYP2C9 enzyme in each patient will facilitate safe 
initiation of warfarin therapy. This approach was the basis of a clinical trial reported by 
Pirmohamed et al80, but contradicted by Kimmel at el81. It is the case that events measured 
in both clinical trials, such as rates of bleeding or thromboembolic events did not differ 
between groups, but these trials were not powered to calculate these outcomes. 
In the case of Thiazide diuretics, there is not yet a clear result ready to make the 
transition from the “bench to bedside”. However there are interesting polymorphisms that 
have been reported using pharmacogenetics and pharmacogenomics during the past years. 
Turner et al82 showed mean declines in SBP and DBP (6±2mmHg and 5±1mmHg) in TT 
than in CC homozygotes in the C825T polymorphism of the gene G-protein β3-subunits 
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(GNB3) in association with HCTZ. A difference in gender response was also found between 
ACE insertion/deletion (I/D) polymorphism and HCTZ by Schwartz et al83. Women with the II 
genotype have greater mean declines in SBP and DBP than DD homozygotes meanwhile in 
the case of men, DD were the ones with greater response than II homozygotes. The 
Glu298Asp polymorphism of the endothelial nitric oxide synthase (NOS3), related to smooth 
muscle relaxation, was associated between African-Americans and European-Americans 
DBP (GG=-8.6±0.4 vs GT+TT=-7.1±0.6) response and HCTZ84. This polymorphism explains 
1% of interindividual variation response to HCTZ. Matayoshi et al85 found a difference 
between responders and non-responders to HCTZ in Japanese individuals with a 
polymorphism in the Na+-Cl- cotransporter SLC12A3 C1784T and in the β3-adrenonergic 
receptor (ADRB3) T727C. The odds ration of the former was 3.81 (C allele vs T allele) and 
of, the latter was 4.59 (T allele vs C allele). The gene WNK lysine deficient protein kinase 1 
(WNK1), has three SNPs86 that have been shown to be associated with ambulatory BP and 
they predict 4% of variation in SBP and DBP responses to HCTZ. In Chinese individuals, 
Lou et al87 found that rs4149601(G/A) in neural precursor cell-expressed developmentally 
downregulated 4-like(NEDD4L) was associated to response in BP due to HCTZ. The A 
carriers had a greater reduction in BP than GG homozygotes (SBP: 6.1mmHg, DBP: 
2.7mmHg).  
 
In one of the first pharmacogenomic studies of its kind, Turner et al88 identified novel 
genes associated with DBP response to HCTZ in a region on chromosome 12. The following 
genes were located in this region: lysozyme (LYS), YEAST domain-containing 4 (YEAST4) 
and fibroblast growth receptor substrate 2 (FRS2). This association was replicated by 
Duarte et al89 in an independent data set of 746 European-Americans and African-
Americans.  
1.7 Specific Aims   
 
My dissertation research investigated the association between genome-wide common 
single nucleotide polymorphism (SNP) variation and the onset of thiazide-induced ADRs in 
multiple samples of primary hypertensive patients. Following this introductory chapter, this 
project dissertation consists in the following aims and chapters: 
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Aim 1 and Chapter 2: Use a genome wide association approach in the GERA and 
PEAR studies to identify loci significantly associated with glucose and triglycerides 
response.  
Linear regression and meta-analysis were used to evaluate the association between 
genome-wide SNP data and HCTZ-induced glucose and triglycerides response in 
unrelated primary hypertensive individuals.   
 
Aim 2 and Chapter 3: Use a genome-wide association approach in the CHARGE 
consortium to identify loci influencing the change in fasting glucose and fasting 
insulin levels after initiating diuretic treatment.  
Longitudinal regression and meta-analysis were used to evaluate the influence single 
nucleotide polymorphism on thiazide-associated changes in fasting glucose and 
fasting insulin levels. 
 
Aim 3 and Chapter 4: Use a genome wide association approach in the GERA and 
PEAR studies to identify loci significantly associated with the change in blood 
potassium levels following HCTZ therapy.  
Linear regression and trans-ethnic meta-analysis were used to evaluate the 
association between the genome data and change in potassium levels due to HCTZ 
in unrelated primary hypertensive individuals. 
 
      The findings from studies are summarized and synthesized in a concluding Chapter 5 
that contains thought regarding the pharmacogenomics antihypertensive field as well as 
future research directions. 
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CHAPTER 2: GENOME-WIDE ASSOCIATION ANALYSES SUGGEST NELL1 
INFLUENCES ADVERSE METABOLIC RESPONSE TO HCTZ IN AFRICAN-
AMERICANS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based upon: Del-Aguila JL, Beitelshees AL, Cooper-Dehoff RM, 
Chapman AB, Gums JG, Bailey K, Gong Y, Turner ST, Johnson JA, Boerwinkle E 
Pharmacogenomics J. 2014 Feb;14(1):35-40. doi: 10.1038/tpj.2013.3 (permission from 
Nature Publishing Group) 
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2.1 INTRODUCTION 
 
Hydrochlorothiazide (HCTZ) is a prescribed drug for treatment of hypertension90 but  
its ability to produce a variety of adverse drug reactions (ADR), such as hyperglycemia 61-63 
and dyslipidemia 49, 59, 60, 63, is well-known. However, the mechanisms of these thiazide-
induced ADRs are not well understood.  
There are two hypotheses about how HCTZ influence the change in concentration 
plasma glucose. The first one states that a relationship between HCTZ-induced 
hypokalemia 49, 91 and impairing insulin secretion is the main cause of the change in glucose. 
The second hypothesis suggested that HCTZ increases visceral and hepatic fat 
accumulation, which could promote insulin resistance [10].  
Other two hypotheses try to explain the of HCTZ-induced dyslipidemia. The first 
hypothesis, which is contradictory 92, 93, suggests that hemoconcentration, caused by the 
volume depletion due to  HCTZ, stimulates the renin-angiotensin-aldosterone system 
(RAAS) thereby stimulating catecholamine release and subsequent adipose tissue lipolysis. 
The second hypothesis is an incremental reduction of lipoprotein lipase activity due to 
interference in the production, release or action of insulin by HCTZ [12].  
This chapter tries to identify the possible molecular mechanisms of these ADR by 
identifying genetic variations that are predictive of inter-individual variation in ADR after 
HCTZ treatment using a genome-wide association study (GWAS). 
 
2.2 MATERIALS AND METHODS 
 
2.2.1 Study population 
Phenotype and genotype data were collected from The Pharmacogenomic 
Evaluation of Antihypertensive Responses (PEAR-clinicaltrials.gov identifier NCT00246519) 
study and the Genetic Epidemiology of Responses to Antihypertensive (GERA- 
clinicaltrials.gov identifier NCT00005520) study. In both studies, participants had mild to 
moderate primary hypertension without a history of heart disease or diabetes mellitus. 
Primary hypertension was defined as blood pressure levels greater than 140/90 mmHg or 
current use of prescription antihypertensive medications in the absence of a known cause 
for elevated BP. If at any time during the study protocols described below the average 
diastolic blood pressure (DBP) rose to greater than 110 mmHg or the systolic blood 
pressure (SBP) to greater than 180mmHg, participants were withdrawn from further study 
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participation and prescribed effective antihypertensive drug therapy. Details about the study 
designs and exclusion and inclusion criteria have been described previously. Briefly, in the 
PEAR study, individuals of any race-ethnicity and gender combination from age 17 to 65 
years old with mild to moderate primary hypertension were recruited. Participants were 
enrolled in Gainesville, Fl; Atlanta, GA; and Rochester, MN. All participants were newly 
diagnosed hypertensives, untreated hypertensives or treated hypertensives taking less than 
three antihypertensive drugs. The protocol of the study was as follows: A wash out period of 
approximately 4 weeks was done in order to remove the effects of previous blood pressure 
medication (if any) from the participants.  If at the end of the wash out period the average 
seated home DBP was > 85mmHg, office DBP was > 90 mmHg and the home and office 
SBP was < 180mmHg the individuals were enrolled into the randomized phase. All biological 
samples (blood and urine) were collected in the fasting state. As soon as the baseline 
evaluations were completed, the individuals were randomized to HCTZ (thiazide diuretic 
12.5mg orally once daily) or atenolol (β-blocker 50mg orally once daily) for three weeks, with 
dose doubling (25 mg) for those with BP > 120/70 mmHg for an additional 6 weeks. More 
than 90% of PEAR participants received the higher 25 mg dose of HCTZ. For this AME 
GWAS analysis, we used only the patients randomized to the HCTZ from the PEAR study, 
referred to hereafter as PEAR HCTZ monotherapy.  
In the GERA study, African-Americans and European Americans with primary 
hypertension were recruited at Emory University in Atlanta, GA and at the Mayo Clinic in 
Rochester, MN, respectively. The protocol for the GERA study was as follows: a wash-out 
period of at least 4 weeks was done in order to remove the effects of previous blood 
pressure medication. If at the end of the wash out period the average office DBP was> 90 
mmHg, qualifying individuals were treated with HCTZ (25 mg orally once daily) for 4 weeks. 
Blood pressure was measured in the seated position using a mercury sphygmomanometer 
and blood samples were obtained for baseline biochemical measurements. At the end of the 
4 week diuretic treatment period, blood pressure was measured and blood samples were 
again obtained for biochemical measurements.  All blood collections were done in the 
morning after 8 hours of fasting. 
All patients enrolled in PEAR and GERA provided written informed consent, and the 
institutional review boards of participating study centers approved the study protocols.94 
 
2.2.2 Phenotype and Genotype data 
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All biomedical measurements were made in a central laboratory at the Mayo Clinic. 
In the PEAR study, these methods were implemented on a Hitachi 911 Chemistry Analyzer 
(Roche Diagnostics, Indianapolis, IN, USA). In the GERA study, plasma glucose 
concentrations were determined by automated spectrophotometric methods implemented on 
an IL Monarch Chemistry system 760 (Instrumentation Laboratories, Lexington, MA, USA). 
Triglyceride concentrations were determined spectrophotometrically using Roche reagents 
on a Cobas Mira analyzer. In both studies, plasma glucose and triglyceride concentrations 
were measured at the end of the wash-out period (baseline) and at the end of the HCTZ 
period (final). Glucose and triglyceride responses to HCTZ were defined as the difference 
between the levels at the final and the baseline visits. Individuals with response values 
under or over 3 standard errors from the mean response were removed from the analysis. 
Plasma insulin, which was used as a covariate during statistical analyses, was measured 
using the Access Ultrasensitive Insulin immunoassay system. 
In the PEAR study, individuals were genotyped on the Illumina HumanOmni1-Quad 
(Illumina, San Diego, California, USA). GERA participants from the opposite extremes of the 
DBP response distribution were genotyped using the GeneChip Human Mapping 500k 
Array, (Affymetrics, Santa Clara California, USA) using standard procedures. As part of 
routine quality control steps, single nucleotide polymorphisms (SNPs) with minor allele 
frequency (MAF) <1%, call rates <95%, Hardy-Weinberg equilibrium p-values ≥10-5 and 
individuals with more than 10% missing genotypes were removed from the analysis. The 
software MACH95 (www.sph.umich.edu/csg/abecasis/MACH/download) was used to impute 
the approximate 2.5 million HapMap SNPs using the Phase II CEU as the reference panel 
for European-Americans and a cosmopolitan sample of CEU and YRI for African-Americans. 
Quality control for the imputed results was done using standard procedures (RSQ_HAT <0.3 
and MAF ≤ 0.05). MACH generated a file with the highest posterior probabilities for each 
imputed SNP which was used in the analysis. After quality control and imputation, there 
were more than 2 million SNPs used for the genotype-phenotype association studies in 
each race-study group.94 
 
2.2.3 Statistical analysis 
 
Analyses were done by self-reported race within each study and later the results 
were combined across studies within races using meta-analysis using a fixed effect model 
weighted by the inverse of the variance of the race and study-specific β-estimates. Linear 
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regression assuming an additive model was performed using ProbABEL to evaluate the 
association between each SNP and metabolic responses to HCTZ. The variables sex, age, 
waist circumference, baseline glucose or triglycerides, and baseline insulin were used as 
covariates.  The inclusion of the baseline value as covariate has both detractor and 
supporters, and our goal was to identify loci that influence change in glucose and 
triglycerides independent of any baseline effects. 
To avoid the possibility of spurious association as the result of population 
substructure, the two first principal component scores (PCS) were used as covariates in the 
analysis. These PCS were obtained using the EIGENSTRAT software 
(genepath.med.harvard.edu/~reich/EIGENSTRAT.htm). After meta-analysis, the definition of 
statistical significance was p<5x10-8 and the same direction of effects (i.e. the sign of β) in 
each study. A statistically suggestive p-value was defined as p<1x10-5 and the same 
direction of effects and was used in order to avoid discounting true positive associations.94 
 
2.3 RESULTS 
 
Baseline characteristics of the European-American and African-American study 
participants are shown in Table 2.3.1 (A and B), which shows the relative similarity in 
participant characteristics between the two studies. In both PEAR and GERA, there were a 
higher percentage of European-American male participants, while for African Americans 
there were a higher percentage of females. Average age and BMI were nearly identical in 
PEAR and GERA. Baseline triglycerides were higher in European Americans from GERA 
compared to the other groups. Response to HCTZ treatment are shown in Table 2.3.2, and 
document  that HCTZ significantly increased glucose and triglyceride in both race groups in 
both studies.94  
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         (A) 
Variables 
PEAR: European 
Americans 
GERA: European 
Americans 
Total 229 196 
Gender(%men) 59.8 57.1 
Age(y) 49.9±9.4 48.5±7.3 
Waist Circumference 
(cm) 
94.8±13.6 103.7±14.7 
Insulin ((μIU/ml) 9.4±8.7 8.5±4.9 
Plasma 
Glucose(mg/dL) 
92.9±12.2 92.4±12.5 
Plasma 
triglyceride(mg/dL) 
149.6±100.9 184.3±97.6 
Systolic blood 
pressure(mmHg) 
151.8±13.5 142.6±12.6 
Diastolic blood 
pressure(mmHg) 
97.9±5.8 95±5.7 
 
 
 
 
          (B) 
Variables PEAR: African Americans 
GERA: African- 
Americans 
Total 148 194 
Gender(%men) 37.84 48.5 
Age(y) 47.4±8.9 47.4±6.3 
Waist Circumference 
(cm) 
97.3±13.5 96.8±14.4 
Insulin ((μIU/ml) 9.9±9.6 12.9±10.1 
Plasma 
Glucose(mg/dL) 
90.8±12.7 97.4±14.4 
Plasma 
triglyceride(mg/dL) 
105.84±93.98 122.4±57.5 
Systolic blood 
pressure(mmHg) 
151.8±13.14 150.8±14.9 
Diastolic blood 
pressure(mmHg) 
97.9±5.8 97.2±5.5 
 
Table 2.3.1 PEAR and GERA sample characteristics measured at baseline94 
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               (A) 
Variables 
PEAR: European 
Americans 
GERA: European 
Americans 
Plasma Glucose 
response (mg/dL) 
1.44±8.9 (p =0.01) 3.03±7.6 (p<0.0001) 
Plasma triglyceride 
response (mg/dL) 
8.21±58.7 (p = 0.2) 14.57±59.9 (p<0.0001) 
 
               (B) 
Variables PEAR: African Americans 
GERA: African 
Americans 
Plasma Glucose 
response (mg/dL) 
2.55±10.8 (p <0.005) 4.3±9.5 (p <0.0001) 
Plasma triglyceride 
response (mg/dL) 
7.95±40.6 (p = 0.02) 9.56±40.3 (p <0.0001) 
   Table 2.3.2 HCTZ treatment response in PEAR and GERA sample94 
 
 
2.3.1 GWAS of adverse effect of HCTZ on glucose: 
 
The meta-analysis of glucose change during HCTZ treatment revealed no SNPs that 
achieved the a priori definition of genome-wide significance in either European Americans or 
African Americans. The Manhattan plots and QQ plots for these analyses are shown in 
Supplement Figure 2.5.1 and Figure 2.5.3 (supplementary information pp. 28-48) However, 
in European Americans 48 SNPs from 8 genomic regions achieved our definition of 
suggestive significance with p < 1x10-5 having effects in the same direction in both studies.  
Likewise, in African Americans 61 SNPs in 12 genomic regions met these criteria. Each of 
these SNPs is summarized in Supplemental         Table 2.5.1, Table 2.5.2 and Table 2.5.5, 
Table 2.5.6 (supplementary information pp. 28-48).94 
 
2.3.2 GWAS of adverse effect of HCTZ on triglycerides: 
 
Among African Americans, two SNPs (rs12279250 and rs4319515 (r2=0.73)) on 
chromosome 11, reached genome-wide significance (β=28 mg/dl, p=6.6x10-9and β=27 
mg/dl, p=4.05x10-8 respectively). The Manhattan plot is shown in Figure 2.3.1, and Figure 
2.3.3 displays the triglyceride response by genotype in both PEAR and GERA.  These SNPs 
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are in the NELL1 gene, whose encoded protein is involved in adipose cell differentiation.  No 
SNPs achieved genome-wide significance for triglyceride response among European 
Americans(supplementary Figure 2.5.2) .  
As was the case with the HCTZ-induced change in glucose, the triglyceride response 
also had many SNPs that met our suggestive significance threshold.  In European 
Americans 25 SNPs in 10 genomic regions met the threshold of p < 1x10-5 with a same 
direction effect, with 77 SNPs in 27 genomic regions meeting this threshold in African 
Americans.  Many of these SNPs were genes previously associated with metabolic 
syndrome, diabetes, insulin and other metabolic traits.  These SNPs are described in detail 
in Supplemental Table 2.5.3, Table 2.5.4 and Table 2.5.7, Table 2.5.8 (supplementary 
information pp 28-48) 94 
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Figure 2.3.1 GWAS meta-analysis Manhattan plot showing the association of triglyceride 
response to HCTZ treatment in African Americans in the PEAR and GERA studies. Two 
SNP on chromosome 11 showed genome-wide significance (p=5 x 10-8). Eighteen loci 
showed p-values less than the suggestive threshold (p=1 x 10-5).94  
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Figure 2.3.2: Regional Plot oon Chromosome 11 showing the position of the top signal 
associated of triglyceride response to HCTZ treatment in African Americans in the PEAR 
and GERA studies 
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Figure 2.3.3: Means change in triglycerides adjusted for sex, age, waist circumference, base 
line insulin, base line triglycerides, and the two principle components depending on 
rs12279250 genotype (CC, CT, TT) for PEAR and GERA studies. Error bars represent 
standard error of the mean.94 
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2.4 DISCUSSION 
 
In this chapter, I performed meta-analyses of GWAS result for the change in plasma 
glucose and triglyceride levels following HCTZ treatment from two biracial pharmacogenetic 
studies consisting of over 425 and 342 individuals, respectively.   
In European Americans, I was not able to identify any locus that met the a prior 
definition of genome-wide significance for the change in glucose and triglycerides levels in 
response to HCZT treatment. However, 73 SNPs (48 SNPs in 8 regions for glucose and 25 
SNPs in 10 regions for triglycerides) reached our criteria of suggestive association.  
In African Americans, change in glucose levels did not met the a prior defined 
genome-wide significance level for a GWAS, however 61 SNPs (13 different regions) 
reached our criteria of suggestive association. In contrast to the above, and in addition to 75 
SNPs in 27 regions that reached our criteria of suggestive association, I was able to identify 
one region marked by two SNPs (rs12279250, p=6.6e-9; and rs4319515, p=4.0e-8) that was 
significantly associated with the change in plasma triglyceride levels in response to HCZT 
treatment. These two SNPs are in high LD and are near the NELL1 gene on chromosome 
11. The NELL-1 protein has osteoinductive properties 96 and has been found to repress 
adipogenic differentiation in both unipotent preadipocytes and imultipotent adipose-derived 
stromal cells97. The regulation of adipose stores through differentiation is tightly controlled, 
with adverse metabolic consequences of disordered fat storage occurring in the setting of 
either too much (obesity) or too little fat (lipodystrophy)98. Therefore, we conjecture that 
HCTZ could be modulating adipocyte differentiation through NELL1 leading to accumulation 
of plasma triglycerides in susceptible patients. Although an interesting finding, this result 
needs to be confirmed in independent studies of hypertensive patients treated with HCTZ.  
For glucose response, It has been hypothesized that the mechanism by which HCTZ 
leads to hyperglycemia involves increased potassium excretion and hypokalemia leading to 
defects in insulin secretion99  However, this hypothesis has been controversial given that 
many genetic causes of chronic hypokalemia (eg Gitelman’s Syndrome) are not associated 
with hyperglycemia or increased risk of diabetes48.  Therefore, it is interesting to note that 
none of the genes identified to be suggestively associated with change in glucose were 
obviously related to potassium transport or excretion49. As such, our results are more 
consistent with a mechanism involving-insulin resistance, perhaps secondary to visceral fat 
redistribution and hepatic fat accumulation as suggested by Eriksson et al.100  
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The strengths of this study include the population based design, the high quality of 
genotyping and phenotyping, the wash out period between drugs as well as the detailed 
follow-up of study participants.  At the same time, we are aware of the limitation posed by 
the small sample size. While under-powered, it is interesting to note that some of the 
suggestive regions described in the Supplementary results were related to previous GWAS 
signals or candidate genes for traits related to type 2 diabetes, obesity, fatty acid 
metabolism, lipid metabolism, glucose metabolism or BMI.  
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2.5 SUPPLEMENTARY INFORMATION 
 
2.5.1 Top SNPs associated with glucose response in European Americans 
 
Forty-eight SNPs reached the suggestive p-value of 1 X 10-5 for glucose response to 
HCTZ in Non-Hispanic whites. These SNPs were located in 8 different chromosomes or 
regions (        Table 2.5.1). The SNPs with the lowest p-values of association in each region 
were selected as index SNPs. These index SNPs were also in high LD with the rest of the 
SNPs in the same region. Table 2.5.2 shows detailed information for index SNPs. 
Chromosome 17 contains the SNP rs11077614, which the lowest p-value (p=2.83e-6) for 
this group. It has a β value indicating that with the presence of each minor allele (G) the 
change in glucose levels are decreased by 3.25 mg/dL. The closest gene to this SNP is the 
solute carrier family 39, member 11 (SLC39A11) which is a metal ion transporter. The index 
SNPs rs6870564, rs890749 and rs6859974 were located on chromosome 5 but in different 
loci. Three other lead SNPs (rs1974942, rs1511453 and rs17644018) were located on 
chromosome 4 but also in different loci. Among the SNPs on chromosome 5, the SNP 
rs6859974 is closed to mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-
acetylglucosaminyltransferase  gene (MGAT1) which is related to fatty acid metabolism101. 
MGAT1 was previously associated with obesity in linkage and GWAS. The SNP rs7762018 
is located on chromosome 6 in the region known as insulin-dependent diabetes mellitus 8 
(IDDM8). This region was associated with type 1 diabetes in an affected-sib-pair analysis, 
and confirmed later in a larger family study and later in a GWAs studies. Other genes in 
these regions have been previously associated with overweight and obesity include 
neuromedin U receptor (NMUR1) and 5-hydroxytryptamine (serotonin) receptor 2B 
(HTR2B). Both genes are closed to rs1669070 (p=4.26e-6) on chromosome 2. A previous 
meta-analysis and candidate gene study have shown a significantly associated risk of Type 
2 diabetes and the polymorphism Thr394Thr(G/A) in the gene peroxisome proliferator-
activated receptor gamma, coactivator 1 alpha (PPARGC1A) in Indians and Asians which  is 
close to rs1511453 (p= 4.71e-6) in chromosome 4  in our study. The Thr394Thr(G/A) 
polymorphism is equivalent to rs2970847, which as a p-value of 0.93 in these data.94 
2.5.2 Top SNPs associated with triglyceride response in European Americans 
 
Twenty five SNP in 10 different chromosomes reached suggestive p-values for the 
change in plasma triglycerides in non-Hispanics whites (Table 2.5.3). The SNP rs17560407 
   
 
29 
 
in chromosome 5 had the lowest p-value (p=5.41e-7) for this phenotype. This SNP is close 
to the myocyte enhancer factor 2C gene (MEF2C) which is reported to be required for the 
expression of GLUT4 gene as well as to be related to type 2 diabetes. Another gene related 
to GLUT4 translocation in adipocytes is the pleckstrin homology-like domain, family B, 
member 1(PHLDB1) located in chromosome 11 (rs11216831, p= 4.11e-6). The list of lead 
SNPs are shown in Table S3.4. rs4722750 (p= 8.51E-6) on chromosome 7 is closed to the 
JAZF zinc finger 1 gene (JAZF1) which was previously identified in a GWAS o type 2 
diabetes. The gene cytochrome c oxidase subunit IV isoform 1 (COX4I1), close to 
rs11648716 (p=7.05e-6) on chromosome 16, was identified as a potential factor in the 
development of type 2 diabetes in a quantitative proteomics approach using mice as an 
animal model. On chromosome 12, the SNP rs12303914 (p= 6.83e-6) is next to the killer 
cell lectin-like receptor subfamily A1 gene (KLRA1), which was identified in a GWAS of end-
stage renal disease (ESRD). The genes cytochrome P450, family 7, subfamily B, 
polypeptide 1 (CYP7B1) on chromosome 8 (rs2980003, p= 4.80e-6) and glutamate-cysteine 
ligase, modifier subunit (GCLM) on chromosome 1 (rs22744788, p= 1.08e-6) have been 
previously related to lipid metabolism.94 
2.5.3 Top SNPs associated with glucose response in African-Americans 
 
Sixty-one SNPs in 12 regions were suggested to be associated with change in 
plasma glucose after HCTZ treatment in African-Americans (Table 2.5.5). Table 2.5.6 
provides details for the lead SNPs within each region. The SNP rs225675, located on 
chromosome 6, had the lowest p-value (p= 1.09e-7) for this phenotype. Among the closest 
genes to this SNP, the G protein-coupled receptor 126 gene (GPR126) was associated with 
BMI in a previous GWAS. Two genes, major facilitator superfamily domain containing 9 
(MFSD9) and branched chain amino-acid transaminase 1 (BCAT1), located on chromosome 
2 near to rs13402330 (p= 5.58e-6) and chromosome 12 near to rs7965364 (p= 6.00e-6), 
respectively, were previously reported in other GWAS of T2D.  In the same region on 
chromosome 2 near rs13402330 resides SCL9A2, a known sodium/hydrogen exchanger 
associated with hypertension. The SNP rs11599315 (p= 5.03e-6) is close to the WD repeat 
domain 37 (WDR37), which was reported to be associated with estimated glomerular 
filtration rate (eGFR). In another region on chromosome 12, the SNP rs7964748 (p=2.45e-6) 
is next to the insulin-like growth factor 1 gene (IGF1) which is associated to fasting insulin 
and insulin resistance (HOMA-IR).94 
 
   
 
30 
 
2.5.4 Top SNPs associated with triglyceride response in African-Americans 
 
There were 77 SNPs in 27 regions that reached the suggestive p-value threshold for 
triglyceride response in African-Americans (Table 2.5.7). Table 2.5.8 shows detailed 
information for the lead SNP in each region. On chromosome 1 and close to rs11810574 (p= 
3.60e-6) is the gene cholinergic receptor muscarinic 3 (CHRM3), which has been associated 
with insulin secretion. The genes ER lipid raft associated 1 (ERLIN1) on chromosome 10 
(rs9420790, p= 1.68e-6) and IQ motif containing GTPase activating protein 2 (IQGAP2) on 
chromosome 5 (rs2460504, p=4.53e-6) have been previously related to liver function. The 
former has been reported to associated with plasma levels of liver enzymes and the latter 
with enhanced hepatic insulin sensitivity. Cholesterol levels have been reported to be 
associated with Calpain 5 gene (CAPN5) located on chromosome 11 (rs10899383, p=6.27e-
6). Genes that have been related to the metabolic syndrome include angiopoietin-like 6 
(ANGPTL6) on chromosome 19 (rs2116940, p=3.39e-6), growth differentiation factor 3 
(GDF3) on chromosome 12 (rs12307997, p=6.24e-7) and ubiquitin-like 5102 (UBL5) on 
chromosome 19 (rs2116940, p=3.39e-6).94 
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Region Name CHR Allele1 Allele2 Position 
Freq 
Allele1 
Direction Β P.value 
Region I rs11077614 17 A G 68106224 0.5066 -- -3.249 2.83E-06 
Region 
II 
A 
rs6870564 5 A G 17056085 0.1295 ++ 3.841 3.57E-06 
rs11959796 5 A T 17059405 0.1293 ++ 3.836 3.68E-06 
rs11953330 5 T C 17059372 0.8707 ++ 3.836 3.68E-06 
B 
rs890749 5 T C 121464495 0.8094 -- -3.246 7.93E-06 
rs1834915 5 A T 121465418 0.1907 -- -3.245 7.93E-06 
rs2560322 5 C G 121467234 0.809 ++ 3.242 7.97E-06 
rs890750 5 T G 121463478 0.8101 -- -3.245 8.10E-06 
rs970041 5 A C 121467568 0.1921 -- -3.212 8.79E-06 
rs1427943 5 A T 121471930 0.1956 -- -3.151 9.94E-06 
C 
rs6859974 5 T C 180138544 0.1431 ++ 3.674 8.37E-06 
rs1021001 5 C G 180136710 0.143 -- -3.676 8.46E-06 
rs7702121 5 A C 180131859 0.1424 -- -3.708 8.55E-06 
Region III 
rs427576 16 A C 72386771 0.5609 -- -2.618 3.88E-06 
rs417278 16 T C 72387977 0.5803 ++ 2.607 5.30E-06 
rs379401 16 C G 72387865 0.5863 -- -2.596 5.56E-06 
Region IV rs1669070 2 T C 231900549 0.403 -- -3.021 4.26E-06 
Region 
V 
A 
rs1511453 4 A G 23197560 0.0762 ++ 4.948 4.71E-06 
rs1397828 4 T G 23205817 0.0717 -- -4.938 4.53E-06 
rs13112409 4 T C 23220756 0.9222 ++ 4.814 6.93E-06 
rs13121520 4 A G 23231629 0.0723 ++ 4.833 5.78E-06 
rs13118539 4 A G 23240961 0.0713 ++ 4.843 6.06E-06 
rs306063 4 A G 23258524 0.0709 ++ 4.913 5.11E-06 
rs3112978 4 T C 23266700 0.0707 -- -4.943 4.75E-06 
rs306054 4 T G 23272551 0.9306 ++ 5.045 3.62E-06 
rs306050 4 A C 23278321 0.0704 ++ 4.960 4.47E-06 
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rs306051 4 A G 23282627 0.9296 -- -4.962 4.46E-06 
rs1948355 4 A G 23306856 0.9307 -- -5.05 5.07E-06 
rs6830932 4 C G 23307048 0.9307 -- -5.051 5.09E-06 
B rs1974942 4 A G 129915671 0.1046 -- -5.296 4.09E-06 
C rs17644018 4 T C 70966894 0.7003 ++ 2.704 1.00E-05 
Region VI 
rs10989824 9 T C 103907659 0.0588 -- -5.850 6.82E-06 
rs7034610 9 A G 103917056 0.0602 ++ 5.724 6.99E-06 
rs10820064 9 A T 103909080 0.0662 ++ 5.632 8.48E-06 
rs10989829 9 A C 103909525 0.0663 ++ 5.627 8.51E-06 
rs10989833 9 T G 103909860 0.0663 -- -5.619 8.55E-06 
rs10989837 9 T C 103910291 0.9336 ++ 5.607 8.65E-06 
rs10989791 9 A G 103857420 0.058 ++ 5.696 9.26E-06 
rs7020246 9 T G 103852964 0.9419 ++ 5.694 9.38E-06 
rs10760837 9 T C 103879660 0.0579 -- -5.735 9.38E-06 
rs1449650 9 T G 103883859 0.0578 -- -5.734 9.63E-06 
rs10820051 9 T G 103884041 0.9422 ++ 5.734 9.67E-06 
Region VII 
rs7762018 6 A C 169855169 0.1325 ++ 3.647 7.50E-06 
rs6923339 6 A T 169869958 0.1326 ++ 3.642 7.71E-06 
rs6941766 6 A G 169873578 0.8673 -- -3.629 8.25E-06 
rs6904601 6 T G 169873830 0.8673 ++ 3.629 8.27E-06 
rs4716342 6 A G 169879884 0.8673 -- -3.628 8.32E-06 
Region VIII rs1551678 10 C G 127819002 0.3706 ++ 2.645 9.30E-06 
        Table 2.5.1 Top 48 SNPs in 8 different regions associated with glucose response in European Americans94 
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     GERA PEAR Meta-analysis 
SNP chr 
Nearby 
gene 
minor 
alleles 
MAFa beta s.e. pvalueb beta s.e. pvalueb beta s.e. pvalue bc 
rs11077614 17 SLC39A11 G 0.49 -3.24 1.27 1.1e-2 -3.25 0.83 8.34e-5 -3.25 0.68 2.83e-6 
rs6870564 5 MYO10 A 0.13 4.55 1.09 2.81e-5 2.85 1.28 2.59e-2 3.84 0.83 3.57e-6 
rs427576 16 - C 0.43 -2.96 0.79 1.79e-4 -2.25 0.81 5.58e-3 -2.62 0.57 3.88e-6 
rs1974942 4 PHF17 A 0.1 -6.12 1.97 1.91e-3 -4.87 1.42 5.76e-4 -5.29 1.15 4.09e-6 
rs1669070 2 
NMUR1/ 
HTR2B 
T 0.4 -2.53 1.09 2.12e-2 -3.29 0.82 5.85e-5 -3.02 0.66 4.26e-6 
rs1511453 4 
PPARGC1
A 
A 0.08 4.78 1.48 1.21e-3 5.14 1.59 1.19e-3 4.95 1.08 4.71e-6 
rs10989824 9 GRIN3A T 0.06 -6.76 1.74 9.93e-5 -4.69 1.96 1.68e-2 -5.85 1.3 6.82e-6 
rs7762018 6 IDDM8 A 0.13 2.49 1.18 3.52e-2 4.69 1.12 2.96e-5 3.65 0.81 7.50e-6 
rs890749 5 LOX C 0.19 -2.90 1.02 4.39e-3 -3.59 1.04 5.14e-4 -3.25 0.73 7.93e-6 
rs6859974 5 MGAT1 T 0.14 3.46 1.17 3.02e-3 3.89 1.17 8.52e-4 3.67 0.82 8.37e-6 
rs1551678 10 ADAM12 C 0.37 2.67 0.83 1.35e-3 2.62 0.85 2.20e-3 2.65 0.59 9.30e-6 
rs17644018 4 CSN1S2A C 0.29 -2.41 0.85 4.45e-3 -3.03 0.89 6.34e-4 -2.70 0.61 1e-5 
Table 2.5.2: Lead SNPs showing association with glucose response to hydrochlorothiazide in meta-analysis of European 
Americans.94 aMinor allele frequency among combined sample of GERA and PEAR.  bP values are based on a linear regression 
adjusted for sex, age, waist circumference, baseline insulin,  baseline glucose and the two first principal components of genetic 
variation for each study. cP values are calculated using inverse-variance meta-analysis 
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Region Name chr Allele1 Allele2 Position Freq Allele1 Direction β P.value 
Region 
I 
rs17560407 5 A G 88219407 0.7389 -- -23.23 5.41E-07 
rs17560451 5 T C 88219759 0.7392 ++ 23.17 5.81E-07 
rs3850653 5 A G 88222710 0.7332 -- -22.99 8.76E-07 
rs244760 5 C G 88146965 0.2657 ++ 23.08 4.34E-06 
Region 
II 
rs2274788 1 T C 94447314 0.7493 -- -23.07 1.08E-06 
Regi
on 
III 
A 
rs11216831 11 A G 117622228 0.0675 ++ 42.47 4.11E-06 
rs12361791 11 T G 117605386 0.9325 ++ 42.51 4.30E-06 
B rs1559759 11 A C 35079627 0.1451 ++ 25.59 8.93E-06 
Region 
IV 
rs2980003 8 T C 66162517 0.2656 ++ 22.07 4.80E-06 
rs2956307 8 A G 66166394 0.2496 -- -22.17 8.75E-06 
Region 
V 
rs12303914 12 A G 10362317 0.3459 ++ 20.39 6.83E-06 
Region 
VI 
rs11648716 16 A G 84464117 0.9213 -- -39.68 7.05E-06 
rs11861580 16 C G 84456048 0.9255 -- -41.76 7.31E-06 
Region 
VII 
rs10943724 6 A C 81359524 0.3051 -- -19.77 7.15E-06 
rs10943725 6 A T 81359702 0.6949 ++ 19.77 7.19E-06 
rs10943726 6 T G 81360629 0.3051 ++ 19.78 7.20E-06 
rs12207977 6 T C 81284893 0.6971 -- -19.53 7.89E-06 
rs4706121 6 A C 81302889 0.2947 -- -19.80 9.68E-06 
Region
VIII 
rs17183114 4 T G 182459721 0.1432 ++ 26.49 7.58E-06 
Region 
IX 
rs4722750 7 T C 27970723 0.1 -- -31.88 8.51E-06 
rs17156099 7 C G 27972967 0.1001 ++ 31.83 8.64E-06 
rs17156100 7 C G 27974909 0.8999 -- -31.78 8.81E-06 
rs2057671 7 T C 27965720 0.1003 -- -32.33 8.82E-06 
rs17156102 7 C G 27975221 0.8999 -- -31.78 8.82E-06 
Region 
X 
rs1724611 15 A G 50647845 0.7341 ++ 30.09 1.05E-05 
Table 2.5.3: Top 25 SNPs in 10 different regions associated with triglyceride response in European Americans94 
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     GERA PEAR Meta-analysis 
SNP chr 
Nearby 
gene 
minor 
alleles 
MAFa beta s.e. pvalueb beta s.e. pvalueb Beta s.e. pvalue bc 
rs1756040
7 
5 MEF2C G 0.27 -18.3 7.35 1.26e-2 -26.4 5.97 9.45e-6 -23.23 4.64 5.41e-7 
rs2274788 1 GCLM C 0.25 -21.1 7.39 4.40e-3 -24.5 6.15 7.04e-5 -23.07 4.73 1.08e-6 
rs1121683
1 
11 PHLDB1 A 0.07 47.5 13.2 3.11e-4 37.6 12.9 3.56e-3 42.47 9.22 4.11e-6 
rs2980003 8 CYP7B1 T 0.27 23.9 7.87 2.37e-3 20.9 6.11 6.03e-4 22.07 4.83 4.80e-6 
rs1230391
4 
12 KLRA1 A 0.35 19.3 7.82 1.36e-2 20.9 5.56 1.66e-4 20.39 4.53 6.38e-6 
rs1164871
6 
16 COX4I1 G 0.08 -53.0 21.3 1.29e-2 -36.9 9.70 1.42e-4 -39.68 8.83 7.05e-6 
rs1094372
4 
6 
BCKDH
B 
A 0.31 -20.4 7.19 4.47e-3 -19.4 5.57 5.08e-4 -19.77 4.40 7.15e-6 
rs1718311
4 
4 - T 0.14 33.9 8.99 1.56e-4 20.8 7.86 8.26e-3 26.49 5.92 7.58e-6 
rs4722750 7 JAZF1 T 0.1 -7.59 10.2 4.57e-1 -55.4 10.05 3.47e-8 -31.88 7.16 8.51e-6 
rs1559759 11 CD44 A 0.15 16.8 9.57 7.92e-2 30.6 7.22 2.24e-5 25.59 5.76 8.93e-6 
rs1724611 15 ARPP19 G 0.27 36.7 12.9 4.40e-3 27.5 8.05 6.33e-4 30.09 6.83 1.05e-5 
Table 2.5.4: Lead SNPs showing association with triglyceride response to hydrochlorothiazide in meta-analysis of European 
Americans.94 aMinor allele frequency among combined sample of GERA and PEAR.  bP values are based on a linear regression 
adjusted for sex, age, waist circumference, baseline insulin,  baseline triglycerides and the two first principal components of genetic 
variation for each study.. cP values are calculated using inverse-variance meta-analysis. 
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Region Name chr Allele1 Allele2 Position Freq Allele1 Direction β P.value 
Region 
I 
rs225675 6 A G 142553829 0.8121 -- -5.286 1.09E-07 
rs225666 6 C G 142539169 0.8127 -- -5.276 1.18E-07 
rs225662 6 T G 142532815 0.181 -- -5.137 2.88E-07 
rs225659 6 A G 142529808 0.181 -- -5.134 2.95E-07 
rs225654 6 A G 142528178 0.8192 -- -5.122 3.19E-07 
rs225653 6 T G 142527112 0.1808 -- -5.119 3.23E-07 
rs225652 6 A C 142526178 0.1808 -- -5.115 3.32E-07 
rs225665 6 A C 142535483 0.1591 -- -5.176 8.22E-07 
rs225643 6 A G 142523539 0.8254 -- -4.755 3.07E-06 
rs628311 6 A C 142509959 0.1789 -- -4.613 5.13E-06 
rs225642 6 T C 142523416 0.1766 -- -4.603 5.15E-06 
rs225641 6 T C 142522696 0.8234 -- -4.593 5.43E-06 
rs225671 6 A G 142542618 0.2914 -- -4.047 5.73E-06 
 rs225674 6 A T 142551860 0.2915 -- -4.047 5.74E-06 
 
rs225676 6 T C 142555919 0.292 -- -4.046 5.79E-06 
rs225635 6 A G 142518431 0.8237 -- -4.564 6.15E-06 
rs2842756 6 T C 142472521 0.1745 -- -4.602 6.59E-06 
rs2842757 6 A T 142474663 0.1745 -- -4.601 6.61E-06 
rs2842758 6 A G 142477424 0.8255 -- -4.599 6.65E-06 
rs225630 6 C G 142515724 0.8238 -- -4.543 6.78E-06 
rs2745470 6 T C 142483233 0.8243 -- -4.559 6.86E-06 
rs639658 6 T G 142509964 0.1761 -- -4.532 7.16E-06 
rs225606 6 A G 142495600 0.8239 -- -4.529 7.23E-06 
rs225622 6 A G 142509080 0.1761 -- -4.529 7.25E-06 
rs225673 6 T C 142547983 0.8453 -- -4.934 9.80E-06 
rs225678 6 A G 142559302 0.1553 -- -4.923 1.01E-05 
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RegionII A 
rs7077606 10 T C 55077097 0.1193 -- -5.439 4.78E-07 
rs7904689 10 T C 55118881 0.89 -- -5.691 5.61E-07 
rs17697015 10 A G 55092707 0.8912 -- -5.402 1.39E-06 
rs2130372 10 A G 55091939 0.1081 -- -5.405 1.43E-06 
rs17622628 10 A T 55011608 0.1172 -- -5.667 1.48E-06 
rs7923617 10 A C 55087496 0.1079 -- -5.365 1.64E-06 
rs7076633 10 T C 55037365 0.8811 -- -5.489 1.77E-06 
rs7095328 10 T C 55055968 0.1211 -- -5.371 2.29E-06 
 
B rs11599315 10 T C 1333017 0.3709 -- -3.883 5.03E-06 
C rs2394354 10 T C 68591112 0.1305 -- -5.455 9.54E-06 
Region  
III 
rs7801534 7 A G 49300226 0.8348 ++ 4.959 6.61E-07 
rs6956707 7 A G 49287553 0.8385 ++ 4.722 4.06E-06 
Region 
IV 
A 
rs7964748 12 A G 101489459 0.7181 ++ 4.057 2.45E-06 
rs7955640 12 T C 101492429 0.2707 ++ 3.926 3.02E-06 
rs1350356 12 T C 101502655 0.3161 ++ 3.463 4.62E-06 
rs10860887 12 A G 101509514 0.6486 ++ 3.344 4.74E-06 
rs1457594 12 T C 101511768 0.6591 ++ 3.314 7.97E-06 
B 
rs10778699 12 A G 78987215 0.2428 ++ 4.277 4.06E-06 
rs7961750 12 T C 79011536 0.5911 ++ 3.589 6.41E-06 
rs7976086 12 C G 79070824 0.64 ++ 3.549 8.58E-06 
C rs7965364 12 T C 25375460 0.3713 ++ 3.799 6.00E-06 
Region V rs12507634 4 A G 175308177 0.8093 -- -4.842 3.70E-06 
Region 
VI 
A 
rs11785622 8 T C 99386915 0.0733 -- -7.215 3.97E-06 
rs17360909 8 A C 99387233 0.9268 -- -7.198 4.06E-06 
rs17288913 8 T C 99387921 0.0721 -- -7.462 4.79E-06 
B rs2944755 8 A G 141643376 0.0598 -- -9.447 7.78E-06 
Region VII 
rs13402330 2 A T 102878724 0.1879 -- -5.269 5.58E-06 
rs10188760 2 C G 102878339 0.188 -- -5.271 5.58E-06 
Region A rs16951120 17 T C 47648637 0.1544 ++ 4.499 6.16E-06 
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VIII rs11867974 17 A G 47649397 0.1544 ++ 4.499 6.19E-06 
B rs12947365 17 T C 2969720 0.7408 ++ 3.881 9.81E-06 
Region IX rs4808260 19 C G 20638111 0.3024 -- -3.713 6.95E-06 
Region X rs6493487 15 A G 49301021 0.9093 ++ 5.959 8.01E-06 
Region XI rs17668704 16 A T 70815200 0.6052 -- -3.383 8.50E-06 
Region XII rs6118476 20 A T 9012332 0.0707 -- -7.148 9.52E-06 
Table 2.5.5 Top 61 SNPs in 12 different regions associated with glucose response in African-Americans94 
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     GERA PEAR Meta-analysis 
SNP 
Ch
r 
Nearby 
gene 
minor 
alleles 
MAFa beta s.e. pvalueb beta s.e. pvalueb beta s.e. pvalue bc 
rs225675 6 GPR126 G 0.19 -4.12 1.38 2.84e-3 -6.56 1.44 5.11e-6 -5.29 0.99 1.09e-7 
rs7077606 10 PCDH15 T 0.12 -6.47 1.49 1.45e-5 -4.30 1.57 5.98e-3 -5.44 1.08 4.78e-7 
rs7801534 7 CDC14C G 0.17 5.14 1.22 2.58e-5 4.6 1.73 7.75e-3 4.96 0.99 6.61e-7 
rs7964748 12 IGF1 G 0.28 4.29 1.13 1.45e-4 3.74 1.33 5.05e-3 4.06 0.86 2.45e-6 
rs1250763
4 
4 FBXO8 G 0.19 -3.43 1.50 2.26e-2 -6.18 1.46 2.28e-5 -4.84 1.05 3.70e-6 
rs1178562
2 
8 NIPAL2 T 0.07 -5.86 2.13 6.02e-3 -8.79 2.30 1.32e-4 -7.21 1.56 3.97e-6 
rs1077869
9 
12 
PPP1R1
2A 
A 0.24 3.04 1.28 1.76e-2 5.65 1.35 2.76e-5 4.28 0.93 4.06e-6 
rs1159931
5 
10 WDR37 T 0.37 -2.99 1.22 1.44e-2 -4.73 1.19 6.75e-5 -3.88 0.85 5.03e-6 
rs1340233
0 
2 
MFSD9/ 
SCL9A2 
A 0.19 -4.97 1.69 3.38e-3 -5.53 1.59 5.05e-4 -5.27 1.16 5.58e-6 
rs7965364 12 BCAT1 T 0.37 5.62 1.15 1.04e-6 1.73 1.23 1.59e-1 3.79 0.84 6e-6 
rs1695112
0 
17 CA10 T 0.15 3.72 1.31 4.44e-3 5.58 1.54 2.81e-4 4.49 0.99 6.16e-6 
rs4808260 19 ZNF626 C 0.30 -3.99 1.07 1.78e-4 -3.29 1.31 1.19e-2 -3.71 0.83 6.95e-6 
rs2944755 8 EIF2C2 A 0.06 -7.39 3.73 4.76e-2 -10.4 2.56 4.84e-5 -9.45 2.11 7.78e-6 
rs6493487 15 
CYP19A
1 
G 0.09 6.90 1.59 1.36e-5 3.68 2.47 1.36e-1 5.96 1.33 8.01e-6 
rs1766870
4 
16 
PMFBM
P1 
A 0.61 -3.99 0.98 4.54e-5 -2.46 1.20 4.09e-2 -3.38 0.76 8.5e-6 
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rs6118476 20 PLCB4 A 0.07 -4.52 2.13 3.43e-2 -10.7 2.47 1.54e-5 -7.15 1.61 9.52e-6 
rs2394354 10 CTNNA3 T 0.13 -2.19 1.79 2.21e-1 -8.38 1.69 7.87e-7 -5.46 1.23 9.54e-6 
rs1294736
5 
17 OR1G1 C 0.26 2.85 1.14 1.28e-2 5.36 1.37 9.03e-5 3.88 0.88 9.81e-6 
Table 2.5.6 Lead SNPs showing association with glucose response to hydrochlorothiazide in meta-analysis of African-Americans94  
aMinor allele frequency among combined sample of GERA and PEAR.  bP values are based on a linear regression adjusted for sex, 
age, waist circumference, baseline insulin,  baseline glucose and the two first principal components of genetic variation for each 
study.. cP values are calculated using inverse-variance meta-analysis. 
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Region Name chr Allele1 Allele2 Position 
Freq 
Allele1 
Direction β P.value 
Region 
I 
A 
rs12279250 11 t c 21521655 0.8538 ++ 28.20 6.60E-09 
rs4319515 11 t c 21534943 0.8629 ++ 27.44 4.05E-08 
rs4923633 11 t c 21496421 0.1038 ++ 28.94 4.07E-07 
B 
rs17133858 11 t g 74649205 0.1393 -- -20.99 5.79E-06 
rs10899383 11 a t 76888784 0.8691 -- -24.09 6.27E-06 
rs17133815 11 a g 74591404 0.1909 -- -18.58 9.36E-06 
Region 
II 
A 
rs2686586 3 t c 169380515 0.4734 ++ 18.93 6.14E-08 
rs2593426 3 a t 169386527 0.5734 ++ 18.45 2.75E-07 
rs2249391 3 a g 169381484 0.4261 ++ 17.81 3.00E-07 
rs2593422 3 t g 169380249 0.424 ++ 17.85 3.02E-07 
rs2249516 3 a g 169380468 0.424 ++ 17.85 3.05E-07 
rs2593423 3 t g 169381964 0.4246 ++ 17.75 3.41E-07 
rs2253178 3 a c 169373412 0.274 ++ 20.22 9.26E-07 
B rs6440957 3 t c 155977646 0.8359 ++ 22.16 7.42E-06 
Region III 
rs12455924 18 t c 11054409 0.3572 -- -17.88 2.91E-07 
rs7228002 18 a g 11058227 0.2579 -- -22.55 5.01E-07 
rs8086223 18 a g 11055122 0.3888 ++ 16.71 8.64E-07 
rs8090641 18 t c 11061006 0.6303 -- -17.17 1.49E-06 
rs7231609 18 a g 11055993 0.412 ++ 15.52 3.89E-06 
rs6505611 18 a g 11054752 0.4137 ++ 14.77 4.39E-06 
rs2870108 18 a g 11053871 0.5862 ++ 14.76 4.44E-06 
rs2870109 18 a t 11053562 0.591 ++ 14.94 4.51E-06 
rs8085688 18 t c 11060641 0.5586 ++ 14.79 7.09E-06 
rs8090173 18 a g 11061287 0.5562 ++ 14.61 7.92E-06 
rs8089847 18 t g 11059798 0.5562 ++ 14.57 7.97E-06 
rs8090019 18 a g 11061197 0.5562 ++ 14.59 7.97E-06 
rs8085263 18 t c 11060338 0.5562 ++ 14.58 7.98E-06 
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rs6505614 18 a g 11059659 0.5562 ++ 14.56 8.00E-06 
Region IV 
rs12307997 12 a g 7746538 0.784 ++ 22.11 6.24E-07 
rs17789655 12 a g 7741253 0.2192 ++ 20.54 8.30E-07 
rs11055277 12 a g 743319 0.1843 ++ 19.77 3.77E-06 
rs7132821 12 a g 7741698 0.8158 ++ 19.77 3.78E-06 
rs11055283 12 a g 7744779 0.1842 ++ 19.76 3.82E-06 
rs7299581 12 a g 7741482 0.1862 ++ 19.29 6.97E-06 
Region 
V 
A rs10152811 15 a c 84655594 0.6948 -- -18.81 8.33E-07 
B 
rs12904863 15 t c 69211063 0.9207 -- -30.13 6.43E-06 
rs1470266 15 c g 69211686 0.9202 -- -29.68 6.81E-06 
rs12914813 15 a t 69226766 0.0815 -- -29.49 7.16E-06 
rs2292854 15 a g 69222676 0.9188 -- -29.47 7.21E-06 
rs16955207 15 a g 69224644 0.9185 -- -29.40 7.31E-06 
rs16955200 15 a g 69224609 0.9185 -- -29.38 7.32E-06 
Region 
VI 
A 
rs10508921 10 t c 51680714 0.1266 -- -25.70 8.76E-07 
rs10825492 10 a g 51678736 0.1542 -- -22.41 1.57E-06 
B 
rs9420790 10 a g 102246187 0.0755 -- -34.63 1.68E-06 
rs4545488 10 a g 102602763 0.054 -- -42.89 6.63E-06 
Region 
VII 
A 
rs12127679 1 t c 242234424 0.1874 ++ 22.31 1.45E-06 
rs12119867 1 t c 242231620 0.804 ++ 22.00 2.39E-06 
rs12122270 1 t g 242237078 0.2016 ++ 19.92 3.19E-06 
rs10927099 1 t c 242236379 0.7931 ++ 19.12 5.55E-06 
rs1156644 1 a g 242234958 0.2232 ++ 18.13 5.64E-06 
rs12119931 1 t g 242234288 0.2049 ++ 19.33 5.92E-06 
rs1319790 1 t c 242234859 0.2036 ++ 19.27 6.11E-06 
rs12126831 1 a c 242234012 0.2047 ++ 19.31 6.16E-06 
rs12126763 1 t c 242233793 0.2032 ++ 19.24 6.63E-06 
B rs11810574 1 a g 238350359 0.8463 -- -23.12 3.60E-06 
Region rs10985375 9 a c 123589463 0.1032 -- -33.94 2.49E-06 
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VIII 
Region IX rs2613514 17 a g 73622113 0.7788 -- -20.12 3.20E-06 
Region X 
rs2116940 19 a g 10171392 0.8057 -- -19.71 3.39E-06 
rs8112895 19 a g 10166162 0.8001 -- -19.33 5.39E-06 
rs10423341 19 a c 10128266 0.1948 -- -19.15 6.54E-06 
rs2241531 19 c g 10132034 0.7997 -- -18.76 9.69E-06 
rs9305012 19 t c 10121869 0.7996 -- -18.61 1.16E-05 
Region XI rs7203315 16 t g 10095561 0.3399 ++ 15.83 3.75E-06 
Region XII 
rs878131 20 a g 45113909 0.2494 ++ 17.21 3.77E-06 
rs947019 20 t g 45107654 0.2534 ++ 17.00 3.80E-06 
rs1417449 20 a g 45106953 0.2535 ++ 16.96 6.18E-06 
Region 
XIII 
A rs166881 6 t c 118725674 0.8222 -- -22.26 3.95E-06 
B 
rs6928289 6 a g 137714995 0.5512 -- -15.56 9.43E-06 
rs4142802 6 t g 137716038 0.4494 -- -15.56 9.74E-06 
rs1521173 6 a t 137718151 0.5504 -- -15.59 9.91E-06 
Region 
XIV 
rs9788333 13 c g 20774096 0.8943 -- -28.65 4.09E-06 
Region 
XV 
A rs2460504 5 c g 76259927 0.1835 -- -24.57 4.53E-06 
B rs2099077 5 a c 102791947 0.2964 -- -16.53 8.25E-06 
Region 
XVI 
A 
rs7147996 14 a t 89466327 0.1163 -- -28.09 5.70E-06 
rs12889533 14 t c 89439502 0.0841 -- -30.50 8.52E-06 
B rs9323104 14 t c 21648621 0.1028 -- -28.78 9.81E-06 
Region 
XVII 
rs12498735 4 t c 185158293 0.2517 ++ 19.13 7.86E-06 
Table 2.5.7 Top 77 SNPs in 27 different regions associated with triglyceride response in African-Americans94 
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     GERA PEAR Meta-analysis 
SNP chr 
Nearby 
gene 
minor 
alleles 
MAFa beta s.e. pvalueb beta s.e. pvalueb beta s.e. 
pvalue 
bc 
rs12279250 11 NELL-1 C 0.15 14.72 8.22 7.33e-2 35.46 6.03 4.09e-9 28.20 4.86 6.60e-9 
rs2686586 3 GOLIM4 T 0.47 15.09 4.92 2.15e-3 22.87 4.97 4.27e-6 18.93 3.59 6.14e-8 
rs12455924 18 FAM38B T 0.36 -18.9 5.31 3.64e-4 -17.1 4.62 2.18e-4 -17.88 3.49 2.91e-7 
rs12307997 12 GDF3 G 0.22 19.5 6.91 4.79e-3 23.9 5.78 3.51e-5 22.11 4.44 6.24e-7 
rs10152811 15 AGBL1 A 0.69 -17.8 5.37 8.56e-4 -19.7 5.43 2.76e-4 -18.81 3.82 8.33e-7 
rs10508921 10 ASAH2 T 0.13 -14.1 7.68 6.61e-2 -35.7 7.13 5.61e-7 -25.7 5.22 8.76e-7 
rs12127679 1 ZNF238 T 0.19 22.85 5.98 1.32e-4 21.49 7.32 3.33e-3 22.31 4.63 1.45e-6 
rs9420790 10 ERLIN1 A 0.08 -19.4 11.87 1.03e-1 -43.6 9.12 1.72-6 -34.63 7.23 1.68e-6 
rs10985375 9 DAB2IP A 0.1 -27.6 10.98 1.19e-2 -38.7 9.56 5.06e5 -33.94 7.21 2.49e-6 
rs2613514 17 TNRC6C G 0.22 -14.2 6.57 3.08e-2 -24.6 5.73 1.73e-5 -20.12 4.32 3.20e-6 
rs2116940 19 
ANGPTL6/ 
UBL5 
G 0.19 -29.2 6.23 2.81e-6 -11.5 5.79 4.67e-2 -19.71 4.24 3.39e-6 
rs11810574 1 CHRM3 G 0.15 -24.9 9.59 9.24e-3 -22.4 5.84 1.23e-4 -23.12 4.99 3.60e-6 
rs7203315 16 GRIN2A T 0.34 17.46 4.96 4.29e-4 14.34 4.73 2.43e-3 15.83 3.42 3.75e-6 
rs878131 20 EYA2 A 0.25 14.84 5.74 6.71e-3 19.25 5.08 1.49e-4 17.21 3.72 3.77e-6 
rs166881 6 SLC35F1 C 0.18 -18.7 7.25 9.86e-3 -25.1 6.46 1.04e-4 -22.26 4.83 3.95e-6 
rs9788333 13 ZDHHC20 G 0.11 -39.6 9.76 4.89e-5 -21.1 8.07 8.79e-3 -28.65 6.22 4.09e-6 
rs2460504 5 IQGAP2 C 0.18 -34.2 7.86 1.32e-5 -16.2 7.33 2.73e-2 -24.57 5.36 4.53e-6 
rs7147996 14 C14ORF14 A 0.12 -28.2 9.74 3.81e-3 -28 8.02 4.74e-4 -28.09 6.19 5.70e-6 
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3 
rs17133858 11 ARRB1 T 0.14 -17.3 6.83 1.12e-2 -24.1 6.29 1.29e-4 -20.99 4.63 5.79e-6 
rs12904863 15 CT62 C 0.08 -43.4 10.42 3.12e-5 -20.9 8.70 1.64e-2 -30.31 6.68 6.43e-6 
rs12498735 4 STOX2 T 0.25 24 7.13 7.61e-4 16.39 5.35 2.21e-3 19.13 4.28 7.86e-6 
rs2099077 5 NUDT12 A 0.29 -12.4 5.53 2.46e-2 -19.9 4.99 6.95e-5 -16.53 3.71 8.25e-6 
rs6928289 6 OLIG3 G 0.45 -14 5.15 6.49e-3 -16.9 4.81 4.33e-4 -15.56 3.51 9.43e-6 
rs9323104 14 - T 0.1 -47.2 11.8 5.80e-5 -20.6 7.82 8.41e-3 -28.78 6.51 9.81e-6 
Table 2.5.8: Lead SNPs showing association with triglyceride response to hydrochlorothiazide in meta-analysis of African-
Americans94 aMinor allele frequency among combined sample of GERA and PEAR.  bP values are based on a linear regression 
adjusted for sex, age, waist circumference, baseline insulin,  baseline triglycerides and the two first principal components of genetic 
variation for each study. cP values are calculated using inverse-variance meta-analysis. 
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Figure 2.5.1 Manhattan and QQ plots of GWAS results for glucose responses to HCTZ in non-Hispanic Whites94 
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Figure 2.5.2 Manhattan and QQ plots of GWAS results for triglycerides responses to HCTZ in non-Hispanic Whites94 
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Figure 2.5.3 Manhattan and QQ plots of GWAS results for glucose responses to HCTZ in African-America94 
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CHAPTER 3: LONGITUDINAL GENOME-WIDE ASSOCIATION FOR INTERACTION OF 
SNPS WITH THIAZIDE DIURETIC USE ON FASTING GLUCOSE AND INSULIN 
LEVELS IN EUROPEAN AMERICANS IN THE CHARGE CONSORTIUM  
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3.1 INTRODUCTION 
 
Diuretics are the most common prescribed antihypertensive drug in the USA89. 
Thiazide diuretics are the first line drug treatment for patients with essential hypertension2 
and 47.5 million filled prescriptions of this drug were dispensed in 200899. Although the 
effectiveness and low cost of this drug are well known, so are its adverse metabolic effects. 
Pharmacogenomics studies (PGXs) of thiazide diuretics seek to identify genetic variants that 
may cause these adverse metabolic effects. Most PGXs are based on clinical trials or 
intervention studies in which the drug is taken, the response for each individual is assessed, 
and differences in response among genotypes are tested. Because of their intensity, these 
intervention studies often suffer from small sample size and low statistical power. However, 
it is possible to do PGX in an observational setting where the patterns of drug use and 
phenotypes levels are measured longitudinally. I used a genome-wide association approach 
with longitudinal data on fasting glucose and fasting insulin levels and diuretic use to identify 
genomic regions influencing adverse metabolic effect. These genome wide association 
studies were carried out in more than 40,000 individuals from the CHARGE consortium’s 
population-based studies. 
 
3.2 MATERIALS AND METHODS 
 
3.2.1 Study populations 
 
All participants were European American descendants that were enrolled in fourteen 
population based cohorts [the Atherosclerosis Risk in Communities (ARIC) study 103, the 
Age-Gene-Environment Susceptibility—Reykjavik Study(AGES)104, Cardiovascular Health 
Study(CHS)105, The Heart and Vascular Health Study(HVH)106, Framingham Heart 
Study(FHS)107, Multi-Ethnic Study of Atherosclerosis(MESA)108, Rotterdam Study 1(RS1)109-
112, Rotterdam Study 2(RS2)109-112, Prospective Study of Pravastatin in the Elderly at Risk / 
Pharmacogenomic study of Statins in the Elderly at risk for cardiovascular 
disease(PROSPER/PHASE)113, the Health, Aging, and Body Composition Study(Health 
ABC)114, Hypertension Genetic Epidemiology Network(HyperGEN)115, Women’s Health 
Initiative (WHI)116, and Coronary Artery Risk Development in Young Adults (CARDIA) 
study117].  The analysis plan described in the statistical methods section was run for each 
cohort. Later on, the findings within each cohort were combined by meta-analysis. 
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Participants from each cohort provided written informed consent, and each study was 
approved by local ethics committees. 
 
3.2.2 Study design exclusion and inclusion criteria 
 
Participants with diabetes at baseline were excluded. The definition of diabetes was 
self-reported history, physician-reported diagnosis of diabetes, fasting glucose levels of 
more than 126mg/dL, non-fasting glucose more than 200mg/dL or use of anti-diabetic 
medications. We also excluded all participants treated with only loop diuretics, due to their 
different mechanism of action in the nephron, and all participants who did not give consent 
for use of their DNA. Participants missing both fasting glucose and fasting insulin or missing 
information on fasting state were excluded. 
 
3.2.3 Definition of drug exposure 
 
Drug exposure was assessed via the method of medication inventory in eleven 
cohorts and by pharmacy information in the other two (RS1 and RS2). We classified a 
participant as exposed to or users of the drug if he or she uses a thiazide or thiazide-like 
diuretic, at each visit, in a single or combination preparation with or without concomitant use 
of a loop diuretic, potassium-sparing diuretic, or potassium supplement. 
 
3.2.4 Measurement of glucose and insulin 
 
Fasting glucose (mmol/L) and fasting insulin (mmol/L) were quantified in each cohort 
by using similar procedures as described previously118, 119. Fasting insulin was natural log-
transformed for analysis    
3.2.5 Genotype arrays and imputation 
 
Each cohort performed their own genome-wide SNP genotyping using different chip 
arrays from either Illumina (San Diego, CA, USA) or Affymetrix (Santa Clara, CA, USA). 
Common quality control steps were followed in all cohorts. SNP with minor allele frequency 
≤1%, call rates <95% Hardy-Weinberg equilibrium p-values <10-5 and individuals with more 
than 10% missing genotypes were excluded. To increase the coverage and facilitate 
interrogation of each SNP among the cohorts, the genotypes were imputed with 
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approximately 2.5 million HapMap SNPs using the Phase II release 22 build 36 and the 
HapMap CEU reference. Quality control for the imputed results was done using standard 
procedures (RSQ_HAT <0.3 and MAF ≤ 0.05) but different algorithms were used among 
cohorts to perform the imputation (Table 3.2.1), such as Bayesian Imputation-Based 
Association Mapping120, Markov chain based haplotyper121 or BEAGLE122. All studies 
inferred unobserved genotypes in a probabilistic manner. 
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Studya Genotyping array 
Genotyp
e calling 
algorith
m 
Imputati
on 
software 
GWAS statistical 
analysis software 
AGES 
Ilumina 
Hu370CNV 
Bead 
Studio 
MACH 
v.1.16 
Boss 
ARIC Affymetrix 6.0 Birdseed 
MACH 
v1.16 
Boss 
CHS Illumina 370CNV 
Genome 
Studio 
BIMBAM 
0.99 
Boss 
CARDIA 
Illumina 
6K/318K/370K 
Bead 
Studio 
MACH 
v 1.0.15 
Boss 
FHS 
Affymetrix 
 500K + 50 MIP 
BRLMM 
MACH 
v 1.0.15 
Boss 
Health ABC Illumina 1M 
Bead 
Studio 
MACH 
v1.16 
Boss 
HyperGEN 
Illumina  
Human610-Quad 
BeadChip 
GenCall MACH Boss 
HVH Illumina 370 
Genome 
Studio 
BIMBAM 
0.99 
Boss 
MESA Affymetrix 6.0 Birdseed 
IMPUTE 
v2.1.0 
Boss 
PROSPER Illumina 660K 
Bead 
studio 
MACH 
v1.15 
Boss 
RS1 Illumina  550k, 
Bead 
Studio 
MACH1 
 v 1.0.15, 
ProbABEL/Boss 
RS2 
Illumina  
550K Duo, 
610KQuad 
Genome 
Studio 
MACH  
v 1.0.16 
ProbABEL/Boss 
WHI CORE 
white 
Affymetrix 6.0 Birdseed 
MACH 
v1.16 
Boss 
WHI BB  
white 
Affymetrix 6.0 Birdseed 
MACH 
v1.16 
ProbABEL 
Table 3.2.1: Genotyping characteristics of the 14 studies included in the pharmacogenomics 
analysis of fasting glucose and fasting insulin participants of European descent. aAll studies 
used HapMap phase 2 release 22 build 36 and the HapMap CEU reference panel for 
imputation. .  AGES, Age, Gene/Environment Susceptibility – Reykjavik Study. ARIC, 
Atherosclerosis Risk in Communities study. HVH, the Heart and Vascular Health Study. 
FHS, Framingham Heart Study. MESA, Multi-Ethnic Study of Atherosclerosis. RS, 
Rotterdam Study. PROSPER, Prospective Study of Pravastatin in the Elderly at Risk. Health 
ABC, Health, Aging, and Body and Composition Study. HyperGEN, Hypertension Genetic 
Epidemiology Network. WHI, Women’s Health Initiative. CHS, Cardiovascular Health Study. 
CARDIA, Coronary Artery Risk Development in Young Adults. 
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3.2.6 Statistical analysis 
 
Within each cohort and when the data were available, we performed either a 
longitudinal analysis or a cross-sectional analysis. We used the overall population design 
that includes drug users and non-users, to allow the separation of the SNP main effect and 
interaction effect estimates. Each drug-genotype interaction was estimated under additive 
genetic model, using the robust variance estimator and an independence working 
correlation (for longitudinal analysis). In the case of cohorts studies, the analysis was carried 
out using ProbABEL123 and “Boss” for longitudinal analysis 124. We used as covariates age, 
sex, study site, body mass index, and ancestry principal components. Two different 
phenotypes of interest were analyzed separately: fasting glucose and log fasting insulin 
levels. 
 
For all of the studies we used the t-distribution as the reference distribution, because the 
number of genetic variants among participants on drug therapy was too small to use 
standard asymptotic results. The total degrees of freedom were calculated as the product of 
the number of drug users, the SNP imputation quality and the SNP minor allele frequencies. 
The p-values were calculated using the original beta over the standard error estimated 
under t-distribution. 
 
The meta-analysis was done using METAL125, applying the standard weighted Z-statistic 
method. The weights were based on the product of: the number of drug users and SNP 
imputation quality. The genome-wide threshold for significant drug-SNP interaction was 
p<5X10-8 and the suggestive threshold was defined as p<1X10-5 
  
3.3 RESULTS 
 
The total number of participants with European ancestry among the 14 cohorts for the 
fasting glucose study was 40226. HVH, WHI and FHS were cohorts that did not use 
longitudinal data for this analysis. In the case of fasting insulin, 12 cohorts out of the 14 
(36923 total participants) have data for the analysis, and FHS, RS1, RS2 and WHI cohorts 
only have baseline phenotype information available. Some basic descriptive statistics are 
shown in Table 3.3.1. There were more women than men participants, and the sample was 
largely middle-aged to elderly. The average range of follow-up data for fasting glucose was 
   
 
55 
 
0.25 to 11.1 years and for fasting insulin it was 1.7 to 9.5 years. The total number of 
autosomal SNPs available for analysis after imputation was 2.5 million. 
 
Figure 3.3.1 and Figure 3.3.2 show the Manhattan and Q-Q plots for fasting glucose and 
fasting insulin, respectively. They show a conservative distribution, with no early departures 
of the p-values from the null expectation. There were no genome-wide significant (p<5*10-8) 
interactions detected for either phenotype. However, there were some suggestive signals 
scattered across the genome that may be of interest to other studies (Table 3.3.2 and Table 
3.3.3). 
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Study/EA 
Glucose 
total 
Glucose 
Cases 
insulin 
total 
Insulin 
Cases 
Glucose Follow-up 
time (mean -sd in 
years) 
Insulin Follow-up 
time (mean-sd in 
years) 
Age,y mean(SD) %Female 
ARIC 8619 1918 8349 1467 3.5 (0.9) 1.7 (0.4) 58.3 (6.5) 53% 
AGES 1561 445 2620 574 5.19 (0.45) 0 74.6(4.75)/79.8(4.76) 62% 
CHS 2752 733 2743 682 6.3 (4.7) 2.4 (1.2) 72.3 (5.3) 62% 
HVH 450 168 - - 0 - 65.7 (8.9) 54% 
FHS 7382 329 6165 223 0 0 46.9(11.9)/47.0(11.9) 46.60% 
MESA 2214 489 2214 415 4.9 (0.3) 9.5 (0.5) 62.4 (10.2) 52% 
RS1 2275 372 5974 223 11.1(0.4) 0 71.1 (6.2) 63.10% 
RS2 3315 144 2157 102 4.1 (0.5) 0 64.4 (7.6)/72.3 (8.6) 55.70% 
PROSPER 4531 1263 - - 0.25 (3 months) - 75.3 (3.5) 52% 
Health ABC 2091 358 1915 339 8.4(3.2) 7.6(4.4) 73.8(2.8) 50% 
HyperGEN 1086 167 1086 166 0 0 48.3(13.7) 50% 
WHI CORE 
white 
855 168 855 180 3.4 (0.8) 3.31 (0.9) 66.1 (7.3) 100% 
WHI BB white 1179 142 1151 140 0 0 66.7 (6.5) 100% 
CARDIA 1703 96 1694 95 5.92(2.26) 5.55 (1.60) 25.7(3.6) 53% 
Table 3.3.1: Baseline characteristics of all cohorts for the analyses of fasting glucose and fasting insulin.  AGES, Age, 
Gene/Environment Susceptibility – Reykjavik Study. ARIC, Atherosclerosis Risk in Communities study. HVH, the Heart and Vascular 
Health Study. FHS, Framingham Heart Study. MESA, Multi-Ethnic Study of Atherosclerosis. RS, Rotterdam Study. PROSPER, 
Prospective Study of Pravastatin in the Elderly at Risk. Health ABC, Health, Aging, and Body and Composition Study. HyperGEN, 
Hypertension Genetic Epidemiology Network. WHI, Women’s Health Initiative. CHS, Cardiovascular Health Study. CARDIA, 
Coronary Artery Risk Development in Young Adults 
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Figure 3.3.1 Manhattan and Q-Q plots of Thiazide SNP interaction estimates for fasting glucose after the meta-analysis from 14 
cohorts of European ancestry 
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SNP CHR BP Alleles GENE feature 
Close  
left_gene 
Close 
right_gene 
Direction  P-value 
rs6668463 1 19891367 T/G TMCO4 
Intron 
[NM_181719.3] 
HTR6 RNF186 +?-+-++++++++? 1.54E-06 
rs11582254 1 19890664 T/C TMCO4 
Intron 
[NM_181719.3] 
HTR6 RNF186 -?+-+-------?? 1.62E-06 
rs4912138 1 19866072 A/G HTR6 
Intron 
[NM_000871.1] 
NBL1 TMCO4 ?---+--------? 2.09E-06 
rs2092018 21 28249480 A/C NA NA RPL10P1 C21orf94 --+-------+--- 2.76E-06 
rs1217798 5 71411704 T/C NA NA CARTPT MAP1B ??--+----+---- 3.58E-06 
rs7072464 10 72456503 T/C NA NA PCBD1 UNC5B ?---+-----+--- 3.86E-06 
rs2028401 7 9152388 A/G NA NA LOC100129634 LOC100132601 ??--+--+------ 3.93E-06 
rs6689496 1 19892631 T/C TMCO4 
Intron 
[NM_181719.3] 
HTR6 RNF186 ??+-+-------+? 4.88E-06 
rs2050120 1 19889499 T/C TMCO4 
Intron 
[NM_181719.3] 
HTR6 RNF186 ??+-+-------+? 5.39E-06 
rs4650679 1 183631346 T/G NA NA IVNS1ABP HMCN1 ?+-++-++-+++++ 6.64E-06 
rs7191944 16 88521379 C/G TUBB3 
Intron 
[NM_006086.2] 
MC1R DEF8 ??--?--------- 7.38E-06 
rs3117941 13 21420118 T/G NA NA FGF9 FTHL7 +?+----+------ 7.50E-06 
rs12499530 4 99391302 A/G NA NA C4orf37 RAP1GDS1 ?-----+--++--- 7.77E-06 
rs4252166 6 161081894 C/G PLG 
Intron 
[NM_000301.1] 
LPA LOC100128831 ?--+?+++++++++ 7.90E-06 
rs7867796 9 112160533 T/C NA NA TXNDC8 SVEP1 -?++-+++-+++++ 8.80E-06 
rs17519029 1 183474050 A/T C1orf26 
Intron 
[NM_017673.6] 
LOC100129295 IVNS1ABP --?-----?---++ 9.29E-06 
rs12648583 4 179143587 A/G LOC285501 
Intron 
[NM_001085490.1] 
LOC285500 LOC391719 
??++-
++++++++? 
9.56E-06 
Table 3.3.2 The SNPs with p-values that reached suggestive values (p<1x10-5) for fasting glucose 
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Figure 3.3.2 Manhattan and Q-Q plots of Thiazide SNP interaction estimates for fasting insulin after the meta-analysis from 12 
cohorts of European ancestry. 
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SNP CHR BP Alleles GENE feature 
Close 
left_gene 
Close 
right_gene 
Direction P-value 
rs433623 5 141348082 C/T RNF14 
utr-3 
[NM_183400.1] 
PCDH12 GNPDA1 ?------++--+ 4.64E-07 
rs3951363 19 21411491 C/T NA NA ZNF493 LOC400680 ?----+------ 1.79E-06 
rs2919378 8 32689211 C/T NRG1 
Intron 
[NM_013964.2] 
LOC100127894 MST131 -?-+---+---- 1.87E-06 
rs2919379 8 32687507 C/T NRG1 
Intron 
[NM_013964.2] 
LOC100127894 MST131 -?-+-------- 2.62E-06 
rs403075 5 141354978 C/T NA NA RNF14 GNPDA1 -++++++--+?? 2.80E-06 
rs4973009 2 232169359 A/G NA NA C2orf57 PTMA ?++-+++-++++ 3.16E-06 
rs7408 5 141360532 A/G GNPDA1 
utr-3 
[NM_005471.3] 
RNF14 MRPL11P2 ?------++-++ 3.48E-06 
rs3856955 4 5825769 C/T EVC 
Intron 
[NM_153717.2] 
EVC2 CRMP1 ?-----+----- 4.82E-06 
rs6758455 2 53307348 A/G NA NA LOC129656 ASB3 ++++++++++++ 5.25E-06 
rs5760783 22 23723897 C/T NA NA TMEM211 CTA-221G9.4 -?------+-?? 5.35E-06 
rs164496 5 141329380 C/T RNF14 
Intron 
[NM_183400.1] 
PCDH12 GNPDA1 ?++++++-++++ 5.83E-06 
rs9386572 6 107161529 C/T RTN4IP1 
Intron 
[NM_032730.4] 
AIM1 QRSL1 ??--++------ 6.29E-06 
rs2546275 4 181804265 C/T NA NA LOC391719 hCG_2025798 +?++++++++?? 6.30E-06 
rs959300 5 122070554 A/G NA NA ARGFXP1 SNX2 ?----+-+---- 6.40E-06 
rs173352 14 55826496 A/G PELI2 
Intron 
[NM_021255.2] 
C14orf34 C14orf101 +?--------?? 7.01E-06 
rs2546270 4 181807433 C/T NA NA LOC391719 hCG_2025798 ??++++++++++ 8.75E-06 
rs11163056 1 80811644 A/G NA NA COX6A1P LOC646538 +++-+-++++++ 9.07E-06 
rs252141 5 141325246 A/G RNF14 
near-gene-
5[NM_183399.1] 
PCDH12 RNF14 ?------+--+? 9.32E-06 
Table 3.3.3 : The SNPs with p-values that reached suggestive values (p<1x10-5) for fasting insulin. 
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3.4 DISCUSSION 
 
Onset of adverse metabolic effects following thiazide or thiazide-like therapy is 
unpredictable. Therefore, if we can identify genomic markers that confer greater risk for 
these adverse effects, we can use them to better understand the biology underlying the 
phenomenon and perhaps predict those individuals who may be susceptible and advise 
them (and their physician) to use alternative antihypertensive therapies. However, one of the 
major limitations to identify the contributing genes (or genomic regions) is the small number 
of individuals in previous GWAS studies using a controlled intervention approach94.  
 
The CHARGE pharmacogenomics group with its 14 large multi-institutional cohorts 
represents the largest effort in detecting genomic loci influencing diuretic response by 
collecting a large number of participating individuals – 40226 in the case of fasting glucose 
and 36923 for fasting insulin. Our meta-analysis did not identify a common SNP (p-value < 5 
X 10-8) conferring high risk for hyperglycemia or hyperinsulinemia among European-
American participants. Lack of positive results in our analysis suggests that it is unlikely that 
there is a single common SNP with a large influence on the adverse metabolic reaction to 
diuretic therapy. I speculate that there may be multiple variants spread throughout the 
genome each with modest effect sizes or a few rare variants with large effect that have a 
greater role in these phenotypes.  
 
This study has limitations. For example, environmental factors such as salt intake were not 
controlled for in these observational studies. Confounding by contraindication resulting from 
comorbidities influencing thiazide diuretic use may also be a factor. However a previous 
simulation showed that these phenomena have very modest effects on estimates of 
interaction in pharmacogenomics studies126. Ascertainment of drug use was based on 
medication inventory or pharmacy data, and the latter is more accurate than the former to 
gauge usage. Finally, the fact that our drug definition is thiazide or thiazide-like diuretic, in a 
single or combination preparation with or without concomitant use of a loop diuretic, 
potassium-sparing diuretic, or potassium supplement may have led to heterogeneous 
effects. These realities may have reduced the sensitivity for detecting SNPs possessing 
important interactive effects. 
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CHAPTER 4: TRANS ETHNIC META ANALYSIS SUGGESTS GENETIC VARIATION IN 
THE HEME PATHWAY INFLUENCES POTASSIUM RESPONSE IN PATIENTS 
TREATED WITH HYDROCHLOROTHIAZIDE. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is based upon: Del-Aguila JL, Cooper-Dehoff RM, Chapman AB, Gums 
JG, Beitelshees AL, Bailey K, Turner ST, Johnson JA, Boerwinkle E 
Pharmacogenomics J. “in press” (permission from Nature Publishing Group) 
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4.1 INTRODUCTION 
 
One adverse effect of thiazide diuretic treatment of hypertension is hypokalemia49, 91. 
Hypokalemia, in turn, may be responsible for impaired insulin secretion56, 127, although this 
hypothesis is not universally supported100, 128. The process by which thiazide diuretics lead to 
potassium wasting and hypokalemia in some patients but not others is not well-understood.  
This chapter is an effort to identify genes or pathways associated with 
hydrochlorothiazide (HCTZ)-induced hypokalemia. To accomplish this goal,  I performed a 
genome-wide association study (GWAS) and a Multi-Ethnic Meta-Analysis (MANTRA)129 in 
European-American and African-American hypertensive patients from two different 
pharmacogenetic studies.  
The results presented here are the first GWAS to our knowledge of diuretic-induced 
potassium loss, and the analysis was conducted in four different study samples (European-
Americans and African-Americans each from two different studies).  
The data implicate the HEME pathway in affecting diuretic treatment-induced 
hypokalemia. 
 
4.2 MATERIALS AND METHODS 
 
4.2.1 Study population 
 
Details of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR, 
clinicaltrials.gov identifier NCT00246519) study and The Genetic Epidemiology of 
Responses to Antihypertensive (GERA, clinicaltrials.gov identifier NCT00005520) study 
have been previously published130, 131. PEAR and GERA study participants were African-
Americans and European-Americans with mild to moderate essential hypertension without a 
history of heart disease or diabetes mellitus. In PEAR, after a wash out period of 
approximately 4 weeks, blood and urine were collected in a fasting state. After the baseline 
evaluations were completed, participants were randomized to HCTZ (thiazide diuretic 
12.5mg orally once daily) or atenolol (β-blocker 50mg orally once daily) for three weeks, with 
dose doubling (to 25 mg HCTZ) for those with BP > 120/70 mmHg for an additional 6 weeks. 
More than 90% of PEAR participants received the higher 25 mg dose of HCTZ. For this 
analysis of potassium (K+) response, we used only those randomized to the HCTZ arm, 
referred to hereafter as PEAR HCTZ monotherapy. 
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In GERA, after a wash-out period of at least 4 weeks, blood samples were obtained 
for baseline biochemical measurement, and then qualifying participants were treated with 
HCTZ (25 mg orally once daily) for 4 weeks. At the end of the 4 week diuretic treatment 
period, blood pressure was measured and blood samples were again obtained for 
biochemical measurements. All blood collections were done in the morning after 8 hours of 
fasting. 
All participants enrolled in PEAR and GERA provided written informed consent, and 
the institutional review boards of participating study centers approved the study protocols. 
4.2.2 Phenotype and Genotype data 
 
Serum potassium concentrations, in PEAR, were measured on a Hitachi 911 
Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN, USA). In GERA, serum potassium 
concentrations were measured by flame photometer (Instrumentation Laboratories model 
943, Lexington, MA). Plasma insulin, which was used as a covariate during statistical 
analyses, was measured in both studies with the Access Ultrasensitive Insulin immunoassay 
system. 
In GERA, serum potassium concentration was determined after 2 weeks of HCTZ 
therapy. In PEAR, serum potassium concentrations were measured at the end of the wash-
out period (baseline), after three weeks and at the end of the HCTZ monotherapy. In both 
studies, there were protocol-mandated potassium supplementation requirements based on 
serum potassium levels.  Potassium supplementation was required for values < 3.6 mmol/L 
in GERA and < 3.2 mmol/L in PEAR.   Potassium supplementation was also available for 
use by the study physician, at their discretion, at higher potassium levels. To avoid 
confounding from prescribed potassium supplementation and to promote patient safety, 
serum potassium response to HCTZ was defined as the difference between the levels 
measured after the first visit (two weeks in GERA case and three in PEAR) of treatment and 
the baseline visit, prior to initiation of potassium supplementation. Thirteen participants with 
potassium response values under or over 3 standard deviations from the mean response 
were removed from the analysis. 
Participants were genotyped using the Illumina HumanOmni1-Quad (Illumina, San 
Diego, California, USA) in the case of PEAR and the GeneChip Human Mapping 500k 
Array, (Affymetrics, Santa Clara California, USA) in the case of GERA. Standard quality 
control steps were applied to the raw genotype data in both studies: single nucleotide 
polymorphisms (SNPs) with minor allele frequency (MAF) <1%, call rates <95%, Hardy-
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Weinberg equilibrium p-values ≥10-5 and participants with more than 10% missing 
genotypes were removed from the analysis. The software MACH95 
(www.sph.umich.edu/csg/abecasis/MACH/download) was used to impute the approximate 
2.5 million HapMap SNPs using the Phase II CEU as the reference panel for European-
Americans and a cosmopolitan sample of CEU and YRI for African-Americans. Quality 
control filters for the imputed results were RSQ_HAT <0.3 and MAF ≤ 0.05. MACH 
generated a file with the highest posterior probabilities for each imputed SNP (i.e. dosage) 
which was used in the analysis. After quality control and imputation, there were more than 2 
million SNPs used for the genotype-phenotype association studies in each race-study 
group. 
4.2.3 Statistical analysis 
 
Additive genetic association analyses of potassium response to HCTZ were 
performed by self-reported race within each study using ProbABEL123, while adjusting for 
sex, age, waist circumference, the baseline values of potassium and insulin, and the two 
first principal component scores (PCS), to avoid the possibility of spurious association as the 
result of population substructure132, 133. The principal components were calculated using the 
EIGENSTRAT132 software. The European-American and African-American GWAS analyses 
were combined via transethnic meta-analysis using MANTRA (Meta-Analysis of Transethnic 
Association studies)129. MANTRA clusters populations by the mean allele frequency 
difference. If populations are in the same cluster, MANTRA assumes that they have the 
same underlying allelic effects and a fixed effect model is performed. On the other hand, if 
populations are in different cluster, the assumption will be that they do not have the same 
underlying allelic effect and a random effect analysis is performed. MANTRA provides a 
combined association signal called a Bayes Factor (BF) instead of a traditional p-value to 
compare the null and alternative hypotheses. A BF of 105, roughly corresponding to a p-
value of 7.9x10-7, was considered significant evidence of association134 after accounting for 
genome-wide multiple comparisons135.   
4.3 RESULTS 
 
Table 4.3.1 A and Table 4.3.1B summarize the baseline characteristics of the 
European-American and African-American study participants, respectively. Both studies had 
a higher percentage of European-Americans male and African American female study 
participants. The average age and waist circumference were nearly identical between PEAR 
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and GERA. Baseline potassium was lower in African-Americans from GERA compared to 
the other groups. The mean response in European Americans was lower compared to 
African Americans. Figure 4.3.1 shows the distribution of potassium response in both 
populations after removing 13 outlier individuals.  
No genome-wide significant association was found in each separate study and race 
group (supplementary information pp 77-90). After the multi-ethnic meta-analysis, the top 
seven SNPs from MANTRA are shown in Table 4.3.2, and four of them, located in three 
different loci, reached genome-wide significance. A Manhattan plot of the BFs is shown in 
Figure 4.3.2. These significant SNPs are: 1) rs10845697 (BF=5.560) on chromosome 12, 
near to the heme binding protein 1 gene (HEBP1), 2) rs1007869 and rs12596186 (LD: 
r2>0.99, BF=5.347 and 5.114 respectively) on chromosome 16, near the junctophilin 3 gene 
(JPH3) and 3) rs11135740 (BF=5.258) on chromosome 8, near to the Mitoferrin-1 gene 
(SLC25A37 also known as MFRN1). The effects of rs10845697 were not consistent among 
study samples (Table 4.3.2). Whether this inconsistency is due to chance sampling 
variation, differences in linkage disequilibrium, or differences in allelic effects among the 
study samples is not known rs12596186 (LD: r2>0.99, BF=5.347 and 5.114 respectively) on 
chromosome 16, near the junctophilin 3 gene (JPH3) and 3) rs11135740 (BF=5.258) on 
chromosome 8, near to the Mitoferrin-1 gene (SLC25A37 also known as MFRN1).  
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(A) 
Variables PEAR: European Americans GERA: European Americans 
Total 229 196 
Gender(%men) 59.8 57.1 
Age(y) 49.9±9.4 48.5±7.3 
Waist Circumference (cm) 94.8±13.6 103.7±14.7 
Insulin ((μIU/ml) 9.4±8.7 8.5±4.9 
Plasma Glucose(mg/dL) 92.9±12.2 95.1±13.2 
Serum Potassium(mEq/L) 4.39±0.441 4.06±0.246 
Systolic blood 
pressure(mmHg) 
151.8±13.5 142.6±12.6 
 
 
 
(B) 
Variables PEAR: African Americans GERA: African- Americans 
Total 148 194 
Gender(%men) 37.84 48.5 
Age(y) 47.4±8.9 47.4±6.3 
Waist Circumference (cm) 97.3±13.5 96.8±14.4 
Insulin ((μIU/ml) 9.9±9.6 12.9±10.1 
Plasma Glucose(mg/dL) 90.8±12.7  101.12±15.6 
Serum Potassium (mEq/L) 4.13±0.48  3.76±0.307 
Systolic blood 
pressure(mmHg) 
151.8±13.14 150.8±14.9  
Table 4.3.1 PEAR and GERA sample characteristics measured at baseline 
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Figure 4.3.1: The distribution of potassium response due to Hydrochlorothiazide in both 
populations. The mean in the distribution was -0.03738(sd = 0.459) in European Americans 
(A), in the case of African Americans (B), it was 0.0483 (sd = 0.475). 
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SNP CHR Position EA 
Nearby 
Gene 
Bayes 
Factor 
rs10845697 12 13076153 G HEBP1 5.560 
rs1007869 16 86174420 T JPH3 5.347 
rs11135740 8 23423702 A SLC25A37 5.258 
rs12596186 16 86174068 A JPH3 5.114 
rs13250356 8 23415776 T SLC25A37 4.984 
rs721183 8 23441779 G SLC25A37 4.982 
rs12095896 1 81723330 C -- 4.980 
Table 4.3.2: Top Seven SNPs from Multi-Ethnic Meta-Analysis. Log10 Bayes factor (BF) 
from the MANTRA analysis. A log10 BF of 5 and higher was considered as a conservative 
threshold for GWAS. EA=effect allele, AA=African American, EU=European American 
 
 
 
 
 
 
 
 
   
 
70 
 
 
 
 
Figure 4.3.2: MANTRA Manhattan plot showing association of potassium response to HCTZ 
treatment in African Americans and European Americans in the PEAR and GERA studies. 
Three SNPs on chromosome 12, 8 and 16 showed genome-wide significance (BF > 5.00). 
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Figure 4.3.3: Regional Plot on chromosome 12 in which SNP rs10845697 is located. The 
gene HEBP1 is the gene related to the Heme pathway 
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Figure 4.3.4: Regional Plot on Chromosome 16 shows the position of rs1007869. The gene 
JPH3 is related to Huntington Disease and chronic kidney disease. 
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Figure 4.3.5: Regional Plot on Chromosome 18. The SNP rs11135740 is located close to 
SLC25A37 gene which is the gene related to the Heme pathway. 
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Because HEBP1 and SLC25A37 are related to HEME synthesis, we carried out a 
targeted analysis of other genes and SNPs related to HEME synthesis. Although 
rs12095896 on chromosome 1 did not reach GWAS significance (BF=4.980), it was found in 
region of the genome previously related to bilirubin levels 
(http://www.genome.gov/gwastudies/index.cfm?pageid=26525384#searchForm). Bilirubin is 
a bile pigment that is a degradation product of HEME. rs10845697 near HEBP1, 
rs11135740 near SLC25A37, and rs12095896 in the bilirubin locus combined accounted for 
5% and 7% of the variance of potassium response in PEAR and GERA European 
Americans, respectively. In African Americans, these values were 16% for PEAR and 12% 
for GERA. The effect size estimates of the top signals from the HEME synthesis pathway 
are shown in Table 4.3.3 
 
 
Effect size (se) 
 
rs10845697 
(close to 
HEBP1) 
 
rs11135740 
(close to 
SLC25A37) 
 
rs12095896 
(close to 
Bilirubin QTL) 
 
 
African 
Americans 
 
 
 
GERA 
 
0.14218 
(0.0454) 
0.13685 
(0.02667) 
-0.09491 
(0.05482) 
 
PEAR 
 
-0.12882 
( .0539) 
0.13461 
(0.02809) 
0.21906 
(0.05015) 
 
European 
Americans 
 
 
GERA 
 
-0.05039 
(0.0401) 
0.13683 
(0.02741) 
-0.05655 
(0.03434) 
 
PEAR 
 
0.18161 
(0.0459) 
0.13410 
(0.02835) 
-0.06223 
(0.03491) 
Table 4.3.3 The effect size estimates from each separate GWAS for each of the top signals 
from trans-ethnic Meta-analysis related to HEME synthesis. 
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4.4 DISCUSSION 
 
Hypokalemia is a well-known adverse effect in patients taking HCTZ. The purpose of 
this study was to identify genes or genomic regions associated with HCTZ-induced change 
in potassium. I conducted a GWAS and MANTRA from two studies of hypertensive 
European American and African American individuals. Four SNPs achieved a log 10 Bayes 
Factor greater than 5 which was defined a priori to be GWAS significant. Confirmation of 
these results will be required in an independent sample of hypertensive patients treated with 
HCTZ. Among the top SNPs, rs10845697 near HEBP1 and rs11135740, near Mitoferrin-1 
(SLC25A37) have a role in heme biosynthesis136-139. Heme has been identified as a 
modulator of the large-conductance Ca2+-activated K+ channels (BK, or maxi K) channels140. 
BK channels are located in the cortical thick ascending limbs141-143, the distal convoluted 
tubule(DCT)144, connecting tubule (CNT)145 and the medullary collecting tubule (MCD) 141-143 
in the kidney. They are sensitive to change in both voltage and calcium concentration and 
they work as volume regulatory channels and secrete potassium146. In the CNT, Thiazide-
induced increased ultrafiltrate delivery to the CNT, this will result in augmented tubular flow 
in CNT promoting BK-dependent K+ secretion at this site. However, they have not 
previously been considered important contributors to renal potassium secretion because of 
their low open probabilities (Po) as well as their low concentration on the principal cell in the 
collecting ducts of the kidney 146. The main route for potassium secretion is considered to be 
the inwardly-rectifying channel, subfamily J, member 1 (ROMK1) encoded by the gene 
KCNJ1 which has higher Po and higher density on principal cells than BK channels
147. 
Although KCNJ1 has shown significant associations with change in glucose in multiple 
studies148, 149, SNPs in and around KCNJ1 were not associated with potassium response to 
HCTZ (data not shown) in this study.  
I hypothesize that HCTZ affects serum K in part by influencing heme levels; the bulk 
of the effect would be inhibition of Na-Cl cotransporter. Heme has been shown to increase 
the Po of the BK channels at negative voltages and to decrease it at more positive 
voltages150. As a result, the secretion of potassium by BK channels would be positively 
associated with heme levels. 
Herein, we report the first GWAS to our knowledge of HCTZ-induced hypokalemia 
and provide evidence for a novel mechanism of HCTZ-induced hypokalemia. Our study is 
unique in that it included a washout of all antihypertensive agents prior to initiation of HCTZ 
and collected detailed data regarding potassium supplementation and levels. However, 
there are weaknesses that must be acknowledged, for instance, although MANTRA can 
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provide an overall Bayes factor as the combined association signal, it fails in estimating a 
proper combined effect size from the joint analysis of all the studies. Another weakness is 
the absence of replication sample. During this study, we contacted multiple potential 
collaborators in the United States and Europe, but none had appropriate potassium 
response data to serve as a replication for this study. This experience underscores the need 
for an international pharmacogenetics of antihypertinsives consortium.  
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4.5 SUPPLEMENTARY INFORMATION 
 
Name CHR Allele1 Allele2 
Freq 
Allele1 
B Position P.valueb 
rs3860285 16 A T 0.1366 0.334355 86177102 1.21E-07 
rs3860286 16 A C 0.1317 0.338087 86177727 1.83E-07 
rs1007869 16 C T 0.8683 -0.33765 86174420 1.84E-07 
rs12596186 16 A G 0.1317 0.33681 86174068 1.85E-07 
rs4843634 16 A T 0.1317 0.335339 86172805 1.88E-07 
rs5026466 16 C G 0.1318 0.334663 86172236 1.89E-07 
rs6540062 16 A C 0.8682 -0.33442 86172138 1.89E-07 
rs4843633 16 G T 0.1317 0.334877 86172592 1.89E-07 
rs17781628 16 A G 0.1318 0.334078 86171795 1.90E-07 
rs17781622 16 A G 0.8699 -0.33537 86171466 2.07E-07 
rs12444907 16 C T 0.8632 -0.33075 86174969 2.52E-07 
rs4843635 16 C G 0.1369 0.32919 86173026 2.52E-07 
rs8059726 16 G T 0.1327 0.328863 86169468 2.53E-07 
rs12444269 16 C G 0.8673 -0.32879 86168628 2.55E-07 
rs17836461 16 A G 0.8673 -0.32878 86168428 2.55E-07 
rs3965791 16 C G 0.8677 -0.32937 86169845 2.57E-07 
rs7124500 11 C T 0.8289 -0.27354 132816875 1.78E-06 
rs12446100 16 C T 0.8689 -0.3178 86164164 2.10E-06 
rs295699 5 A T 0.3745 -0.21468 73732248 2.72E-06 
rs3909525 16 A G 0.1362 0.309976 86161146 2.91E-06 
rs4833034 4 C T 0.3455 -0.2197 37994749 3.38E-06 
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rs17215757 4 C T 0.0559 0.455013 182896313 3.64E-06 
rs7481213 11 C T 0.8288 -0.26326 132844528 4.11E-06 
rs7481500 11 G T 0.8277 -0.26268 132839560 4.13E-06 
rs7926647 11 C T 0.173 0.259554 132827521 4.55E-06 
rs11223474 11 A T 0.8267 -0.259 132824185 4.66E-06 
rs10474415 5 A C 0.3724 -0.21108 73730174 4.89E-06 
rs3912201 14 C T 0.591 0.206028 55664173 5.00E-06 
rs7349056 22 A G 0.8351 -0.49493 22061801 5.88E-06 
rs7871887 9 C T 0.1336 -0.319 99611263 7.00E-06 
rs3911953 3 A G 0.3848 -0.20546 73880249 7.56E-06 
rs3845885 3 C T 0.3848 -0.20544 73881112 7.63E-06 
rs2309536 4 C T 0.906 -0.35428 182870193 8.17E-06 
rs2961071 7 A T 0.3574 0.204126 141407299 8.18E-06 
rs11586466 1 C T 0.6833 0.349123 94892799 8.61E-06 
rs17779898 4 A C 0.2737 0.22088 73987351 9.21E-06 
rs6590698 11 C G 0.7902 -0.24367 132819450 9.44E-06 
rs7127798 11 A G 0.2093 0.244889 132816986 9.59E-06 
rs7112051 11 C T 0.2127 0.243601 132852125 9.97E-06 
rs6590712 11 A C 0.7874 -0.24358 132854916 9.98E-06 
Table 4.5.1: Top 40 SNPs associated with potassium response in European Americans in 
the GERA study (p<10-5)bP-values are based on a linear regression adjusted for sex, age, 
waist circumference, baseline insulin, baseline potassium and the two first principal 
components. 
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Name CHR Allele1 Allele2 
Freq. 
Allele1 
B Position P.valueb 
rs8121649 20 C T 0.9 -0.277999 49514051 2.17E-07 
rs6091326 20 C T 0.8999 -0.277314 49514749 2.27E-07 
rs17728712 20 A G 0.2259 0.222402 49497628 2.71E-07 
rs6096436 20 A T 0.2267 0.222387 49497963 2.72E-07 
rs880324 20 A G 0.2066 0.226564 49487597 3.87E-07 
rs1457501 3 G T 0.0787 0.409515 90391748 1.41E-06 
rs12415289 10 G T 0.945 -0.396245 65594256 1.82E-06 
rs7962710 12 C T 0.5521 -0.185898 38650369 1.85E-06 
rs6722679 2 A G 0.1274 0.301391 233641663 1.92E-06 
rs9865917 3 A G 0.1263 0.295705 112649698 1.97E-06 
rs9856827 3 C T 0.8734 -0.295608 112642842 1.99E-06 
rs1909095 3 C T 0.1349 0.294155 112636191 2.73E-06 
rs7807828 7 C T 0.63 -0.195253 42533677 3.03E-06 
rs984809 7 C G 0.938 -0.425247 16324952 3.18E-06 
rs4720429 7 A G 0.3686 0.194047 42524143 3.23E-06 
rs6708049 2 C T 0.8761 -0.292945 233651537 3.23E-06 
rs10877877 12 C G 0.4509 0.180851 38653720 3.32E-06 
rs4428577 7 G T 0.6267 -0.192542 42564495 3.83E-06 
rs757522 7 C G 0.052 0.419761 16330134 4.09E-06 
rs10237886 7 C T 0.0518 0.419453 16335031 4.15E-06 
rs2158485 7 C T 0.0518 0.419453 16332864 4.15E-06 
rs7779204 7 A G 0.0519 0.419453 16335490 4.15E-06 
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rs2389595 7 C T 0.9481 -0.419468 16338850 4.15E-06 
rs6949613 7 A G 0.0519 0.419468 16341806 4.15E-06 
rs6461240 7 A G 0.9482 -0.420007 16341948 4.18E-06 
rs6785666 3 A C 0.5222 -0.187893 22551549 4.34E-06 
rs1074612 3 A C 0.5224 -0.18788 22554572 4.36E-06 
rs9874439 3 A T 0.4771 0.187885 22556225 4.44E-06 
rs12638304 3 G T 0.477 0.187885 22556385 4.45E-06 
rs4520070 7 G T 0.6268 -0.190643 42554149 4.58E-06 
rs16858101 3 C T 0.121 0.301383 112664498 5.11E-06 
rs12667487 7 A G 0.6239 -0.190391 42545153 5.57E-06 
rs1818903 7 C T 0.3775 0.189731 42565109 5.75E-06 
rs11232492 11 C T 0.8678 -0.304302 80531648 5.75E-06 
rs9873792 3 A C 0.867 -0.297479 112704293 5.96E-06 
rs4634534 7 C T 0.627 -0.188859 42579215 6.69E-06 
rs1589794 7 A C 0.627 -0.188775 42570889 6.79E-06 
rs6506850 18 A C 0.9321 -0.359879 74594768 6.80E-06 
rs4355689 7 C T 0.3775 0.187896 42554082 6.82E-06 
rs1357772 7 C T 0.3774 0.187767 42552488 6.90E-06 
rs1524798 3 C T 0.8174 -0.227436 83849028 6.97E-06 
rs10032745 4 G T 0.7925 -0.21749 110118152 6.97E-06 
rs4856466 3 C T 0.8174 -0.22736 83856031 6.99E-06 
rs9828223 3 C T 0.8781 -0.29863 112707615 7.04E-06 
rs11663063 18 C T 0.0541 0.412155 27827523 7.07E-06 
rs1357797 3 A G 0.1825 0.227114 83857768 7.13E-06 
rs2941831 18 A G 0.0744 0.329674 74623976 7.19E-06 
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rs3863122 4 G T 0.2078 0.216103 110118295 7.36E-06 
rs3863125 4 A G 0.2077 0.216218 110118726 7.42E-06 
rs1949050 11 C T 0.5388 0.174517 108437543 7.58E-06 
rs13433798 3 A G 0.8892 -0.312413 112678830 7.68E-06 
rs1524790 3 A T 0.8157 -0.226553 83836660 8.05E-06 
rs1873407 3 C T 0.5052 -0.182601 195176275 9.40E-06 
rs1729791 12 C T 0.5351 -0.171664 57051720 9.43E-06 
rs1349272 3 C T 0.5024 0.1851 22502129 9.51E-06 
rs1949052 11 A G 0.5688 0.172612 108437872 9.72E-06 
Table 4.5.2: Top 56 SNPs associated with potassium response in European Americans in 
the PEAR study (p<10-5) bP-values are based on a linear regression adjusted for sex, age, 
waist circumference, baseline insulin, baseline potassium and the two first principal 
components. 
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Name CHR Allele1 Allele2 
Freq. 
Allele1 
B Position P.valueb 
rs7715999 5 A G 0.8832 -0.532961 82111381 7.63E-08 
rs1842249 5 G A 0.8988 -0.430565 25773621 5.32E-07 
rs2885404 17 C T 0.9433 -0.786045 63931228 9.08E-07 
rs583807 6 G A 0.8991 0.343969 4100791 1.69E-06 
rs6891558 5 C G 0.889 0.447258 132682700 2.31E-06 
rs4474027 8 A G 0.8967 -0.309752 9514775 3.27E-06 
rs9693430 8 G T 0.9444 -0.49321 130034016 4.21E-06 
rs11128214 3 C T 0.8886 0.327577 71545572 4.30E-06 
rs17242435 8 G A 0.9442 -0.491735 130039930 4.36E-06 
rs17820673 8 C A 0.9442 -0.491208 130043811 4.44E-06 
rs8063994 16 A G 0.2708 -0.253213 82678219 4.75E-06 
rs12700592 7 G A 0.892 -0.354379 24987645 4.97E-06 
rs12537228 7 C T 0.8922 -0.35382 24986390 5.10E-06 
rs9537937 13 A T 0.7981 -0.232819 57546600 6.17E-06 
rs11022391 11 G A 0.9446 -0.514256 12506759 6.23E-06 
rs1453830 11 A G 0.4072 0.197476 132485784 6.44E-06 
rs10750531 11 A G 0.4072 0.197391 132486275 6.47E-06 
rs1431780 11 A G 0.4072 0.197274 132486656 6.50E-06 
rs9537878 13 G A 0.7986 -0.235714 57433793 6.59E-06 
rs260555 3 C A 0.591 -0.233258 590153 7.18E-06 
rs4767276 12 T A 0.8753 -0.497512 113798811 7.39E-06 
rs7704137 5 A C 0.3885 -0.241164 174582300 8.98E-06 
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rs11096569 2 A G 0.7156 -0.233028 19075754 9.01E-06 
rs7369021 2 A G 0.7156 -0.23304 19076521 9.02E-06 
rs13180965 5 G A 0.866 -0.26733 7240278 9.32E-06 
rs10060705 5 C T 0.7368 -0.226592 63937060 9.74E-06 
Table 4.5.3 Table S3: Top 26 SNPs associated with potassium response in African 
Americans in the GERA study (p<10-5). bP-values are based on a linear regression adjusted 
for sex, age, waist circumference, baseline insulin, baseline potassium and the two first 
principal components. 
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Name CHR Allele1 Allele2 
Freq. 
Allele1 
Beta Position P.valueb 
rs6047645 20 A G 0.8442 -0.340436 21748445 1.31E-07 
rs2722265 7 G A 0.3501 0.246094 37653661 4.52E-07 
rs2598064 7 C A 0.35 0.245905 37655181 4.59E-07 
rs10216297 7 T C 0.3452 0.248814 37653087 4.80E-07 
rs16842009 2 C T 0.9278 -0.51318 158419778 4.86E-07 
rs6113381 20 C T 0.8968 -0.409101 21732950 6.80E-07 
rs12625990 20 A G 0.8968 -0.40913 21726684 6.96E-07 
rs10243276 7 G T 0.355 0.238874 37648975 8.91E-07 
rs2722236 7 T G 0.3549 0.238803 37649086 8.94E-07 
rs13220395 6 G A 0.9259 -0.432178 26163347 9.08E-07 
rs2722235 7 C T 0.3547 0.238435 37649155 9.20E-07 
rs10265204 7 G A 0.3546 0.238241 37650935 9.34E-07 
rs2722269 7 G A 0.3544 0.237915 37652206 9.59E-07 
rs2598054 7 T C 0.3459 0.236483 37657880 1.00E-06 
rs2722252 7 A G 0.3451 0.236408 37658017 1.02E-06 
rs2598053 7 G A 0.3458 0.23628 37658209 1.02E-06 
rs6971034 7 A C 0.3463 0.236205 37666837 1.04E-06 
rs2722333 7 G A 0.3462 0.23616 37666459 1.04E-06 
rs2598046 7 G A 0.3457 0.235914 37662047 1.05E-06 
rs2722360 7 A T 0.3457 0.23591 37662160 1.05E-06 
rs2598042 7 G A 0.3558 0.237593 37663829 1.15E-06 
rs2598043 7 G A 0.3557 0.237583 37663821 1.15E-06 
rs2598044 7 T C 0.3557 0.237534 37663556 1.15E-06 
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rs2722372 7 A G 0.3557 0.237534 37663507 1.15E-06 
rs6888729 5 T C 0.6548 -0.254523 35801938 1.68E-06 
rs2722266 7 A G 0.3341 0.240984 37652728 1.89E-06 
rs2722260 7 C T 0.3532 0.233249 37655782 1.92E-06 
rs2722267 7 A G 0.3339 0.241107 37652567 1.93E-06 
rs12535173 7 G T 0.3575 0.233175 37655846 1.94E-06 
rs2722257 7 A G 0.3531 0.233082 37656111 1.95E-06 
rs2722256 7 A G 0.353 0.232733 37656438 2.01E-06 
rs2598061 7 A C 0.353 0.232666 37656712 2.02E-06 
rs13200797 6 G A 0.9102 -0.43268 26230936 2.09E-06 
rs10247167 7 C T 0.9177 -0.433858 144716323 2.43E-06 
rs10233894 7 A G 0.9182 -0.436268 144734048 2.44E-06 
rs9566765 13 T C 0.8128 -0.387312 40902497 2.65E-06 
rs17586553 6 G A 0.9276 -0.426277 26036754 2.96E-06 
rs13195279 6 T A 0.9293 -0.42619 26027410 2.96E-06 
rs2598052 7 G T 0.3515 0.227805 37658294 3.01E-06 
rs17587226 6 C T 0.9312 -0.435172 26070283 3.43E-06 
rs2328642 20 C G 0.7638 -0.243085 21754161 3.65E-06 
rs10519916 15 T C 0.8907 -0.347048 32321272 3.65E-06 
rs7205902 16 G C 0.8368 -0.306934 25120016 3.71E-06 
rs13207673 6 C T 0.9345 -0.430981 26009112 3.82E-06 
rs13208859 6 G A 0.9345 -0.430874 26002588 3.84E-06 
rs13220488 6 A G 0.9346 -0.430874 26004886 3.84E-06 
rs13241942 7 A G 0.3384 0.23217 37651206 3.94E-06 
rs11696327 20 C T 0.7581 -0.237324 21757409 4.44E-06 
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rs457864 21 C A 0.8957 -0.374412 27093797 4.48E-06 
rs10484435 6 T G 0.9279 -0.416692 26139790 4.63E-06 
rs730549 16 G A 0.2899 -0.238479 73788556 4.86E-06 
rs2722254 7 C G 0.367 0.227112 37657353 5.03E-06 
rs12095896 1 A C 0.605 -0.226253 81723330 5.40E-06 
rs889511 16 C T 0.5157 -0.215175 73789170 6.27E-06 
rs643014 11 A G 0.8853 -0.301209 117493433 6.39E-06 
rs7870338 9 A C 0.6603 0.254412 89432342 6.77E-06 
rs10775183 15 C A 0.8083 -0.275077 61077587 7.34E-06 
rs1587837 8 T G 0.5337 -0.204157 91897240 7.85E-06 
rs1875901 8 T C 0.5338 -0.204104 91895883 7.85E-06 
rs12680488 8 G A 0.5368 -0.203451 91891456 7.91E-06 
rs1818193 8 A G 0.5373 -0.202426 91886818 7.92E-06 
rs1504791 8 G A 0.5526 -0.209589 91904312 8.42E-06 
rs1504792 8 A C 0.5526 -0.209536 91904233 8.45E-06 
rs1862736 16 G C 0.4848 -0.212898 73786041 8.77E-06 
rs4787696 16 G A 0.8724 -0.318475 25108484 9.04E-06 
rs1542931 8 C G 0.5555 -0.20822 91892744 9.09E-06 
rs1436849 12 C T 0.3077 0.245046 64861385 9.09E-06 
rs6498423 16 G A 0.6164 -0.217535 13531381 9.22E-06 
rs12681868 8 G A 0.5556 -0.207585 91888527 9.43E-06 
Table 4.5.4: Table S4: Top 69 SNPs associated with potassium response in African 
Americans in the PEAR study (p<10-5). bP-values are based on a linear regression adjusted 
for sex, age, waist circumference, baseline insulin, baseline potassium and the two first 
principal components 
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Figure 4.5.1: Manhattan and QQ plots of GWAS results for potassium responses to HCTZ in European Americans in the GERA 
Study. 
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Figure 4.5.2: Manhattan and QQ plots of GWAS results for potassium responses to HCTZ in European Americans in the PEAR 
Study. 
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Figure 4.5.3Manhattan and QQ plots of GWAS results for potassium responses to HCTZ in African-Americans in the GERA Study.  
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Figure 4.5.4: Manhattan and QQ plots of GWAS results for potassium responses to HCTZ in African-Americans in the PEAR Study.  
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CHAPTER 5: SYNTESIS AND FUTURE DIRECTIONS 
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5.1 SYNTHESIS 
 
Pharmacogenomics is a promising component of the broader field of personalized 
medicine. The concept behind it is to use genomic information to prescribe the right drug for 
each person in order to increase efficacy and decrease side effects. This dissertation 
focused on identifying and quantifying genetic factors that contribute to hydrochlorothiazide 
adverse metabolic effects among European and African Americans. This final chapter 
provides a brief synthesis of information across the previous chapters and an indication of 
future directions of the field. 
Chapter 2 showed the results of a GWAS performed to evaluate the association 
between each SNP and change in glucose and triglycerides due to HCTZ treatment. Only 
an intronic SNP at the NELL1 gene showed association between the change in triglycerides 
and HCTZ treatment in African Americans. This gene is related to adipocyte differentiation 
which led me to hypothesize that HCTZ could be modulating adipocyte biology through 
NELL1 leading to an accumulation of plasma triglycerides in susceptible patients. It is worth 
to mention that by the time that this dissertation was completed, a new GWAS paper was 
published by Rudkowska151 in which NELL1 came up as a top hit in the association 
between triglyceride response to n-3 PUFA supplementation. No significant association was 
found in the case of change in glucose and HCTZ treatment.  
The studies from the previous chapter were carried out in an interventional setting, but it 
is possible to test pharmacogenetic hypotheses in an observational setting. Chapter 3 used 
a longitudinal analysis approach in the CHARGE consortium to test hypotheses about the 
genetic predictors of the change in fasting glucose levels after taking a diuretic over time. 
This analysis consisted of 7,038 individuals from 14 cohort studies. No significant 
interaction was found between diuretic usage and any SNP with the change in glucose 
levels. This negative result suggested that the rare variant approach could have the answer 
instead of the common variant approach for my question. 
It has been hypothesized that the mechanism by which HCTZ leads to hyperglycemia 
involves increased potassium excretion and hypokalemia leading to defects in insulin 
secretion (Duarte et. al. 2010 Expert Rev CardiovascTher; 8, 793-802), but the 
mechanisms underlying this phenomenon are not well-understood. Chapter 4 dealt with this 
hypothesis. To increase the power of the analysis, I ran a trans-ethnic meta-analysis which 
clusters populations by the mean allele frequency difference. If populations are in the same 
cluster, we will assume that they have the same underlying allelic effects and a fixed effect 
model is performed. On the other hand, if populations are in different clusters, the 
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assumption will be that they do not have the same underlying allelic effect and a random 
effect analysis is performed. In this analysis, I was able to find an interesting relationship 
between the Heme pathway and change in potassium. Heme has been identified as a 
modulator of the large-conductance Ca2+-activated K+ channels (BK, or maxi K channels) 
(Tang et. al. 2003 Nature; 425, 531-5). These channels are located in the medullary and, 
the cortical thick ascending limbs and the distal convoluted tubule in the kidney and they 
secrete potassium (Pluznick et. al. 2006; Am. J Physiol. Renal Physiol. 291, F517-F529). 
However, they have not previously been considered important contributors to renal 
potassium secretion because of their low open probabilities (Po). I hypothesize that HCTZ 
affects serum K in part by increasing Heme.  
This dissertation research showed some interesting results, but the question about the 
genetic predictors of the change in glucose levels and the onset of diabetes levels following 
diuretic usage remains elusive. One explanation is that the primary genetic predictors are 
the result of rare variants with large effects. These rare variants would not have been 
detected by the GWAS methods used here.  Sequencing is becoming the norm in modern 
human genetics152, and it will likely move in that direction for pharmacogenetics. The field is 
moving from a common variant/common disease hypothesis or model to a rare 
variant/common disease hypothesis or model. However, this does not mean that AME is a 
simply inherited phenotype or Mendelian condition. Rather, this new hypothesis states that 
multiple rare variants influence the trait of interest. Over the population, these variants can 
reside in a single gene or multiple genes that have cumulative effects. Likewise, they may 
reside in multiple genes in the sample pathway. Pharmacogenetic researchers can use 
either whole-exome sequencing (WES) or whole-genome sequencing (WGS) to find 
association with drug response traits. Such large scale sequencing efforts have already 
begun in the CHARGE consortium. 
 
5.2 THOUGHT AND FUTURE DIRECTIONS 
 
Many polymorphisms associated with pharmacodynamics and pharmacokinetics have 
been identified for drugs such as antithrombotic agents, B-adrenergic receptor blockers, 
statins, and angiotensin-converting enzyme inhibitors and diuretics however most of these 
results do not replicate in other studies or are inconsistent. Therefore, the impact of this 
information in clinical outcomes as well as in clinical practice is still on hold  
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A possible reason for this inconsistent is the study design; some of them tend to be bias 
or more likely confounding problems. I agree with Kurland et al153 that the ideal 
pharmacogenomic study should be prospective, use one drug at the time, include naïve 
hypertensive individuals and include a placebo arm. But, I know that followed these 
conditions are logistically difficult, costly and unethical (placebo-treatment).  
Another problem is the definition of the phenotype across different studies. For 
instance, the use of clinical or ambulatory blood pressure measurements as outcome must 
be the same in all the different studies that are used for comparison. 
Sample size, which leads to problems with insufficient statistical power, is another 
difficulty that we face in these pharmacogenomic studies and can produce spurious results. 
 As biologists, I tend to like a simple explanation for any disease or pathway, this 
oversimplification in thoughts tend to create hypotheses that exclude biological and 
environmental interaction, which gives us partial information of how diseases and its 
response to treatment really behave. 
Important variables, sometimes over-looked during the comparison of 
pharmacogenomic antihypertensive studies, are not only drug dose but drugs within the 
same class (hydrochlorothiazide vs chlorthalidone or atenolol vs metoprolol) that may have 
different pharmacologic properties which lead to inconsistent results.  
The formation of a new consortium known as International Consortium for 
Antihypertensive Pharmacogenomics Studies (ICAPS) promises to faced most of the 
problems describe in previous paragraphs in order to provide real genetic information that 
can be used for clinical practice. The consortium is formed by different cohorts in different 
continents. America is represented by Minesota-GERA and Florida-PEAR, Europe by Italy-
PHSS, MILAN, Scotalnd-NORDIL and Finland-GENRES and Asia by China-FEVER_PGx. 
And although, most of the cohorts are based on European descends, other ethnicities are 
part of it. These cohorts are based on interventional studies, most of them used one drug, 
but if different drugs are used they were at different arms of the study or after some wash 
out period. I am hoping that these cohorts will increase our sample size and power to detect 
common and rare variants responsible for AMEs.  
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